{"title": "The Role of Macrophages in HIV-1 Persistence and Pathogenesis", "pubDate": "2019", "PMCID": "PMC6906147", "DOI": "10.3389/fmicb.2019.02828", "PMID": "31866988", "abstract": "Current antiretroviral therapy (ART) effectively suppresses Human Immunodeficiency Virus type 1 (HIV-1) in infected individuals. However, even long term ART does not eradicate HIV-1 infected cells and the virus persists in cellular reservoirs. Beside memory CD4+ T cells, cells of the myeloid lineage, especially macrophages, are believed to be an important sanctuary for HIV-1. Monocytes and macrophages are key players in the innate immune response to pathogens and are recruited to sites of infection and inflammation. Due to their long life span and ability to reside in virtually every tissue, macrophages have been proposed to play a critical role in the establishment and persistence of the HIV-1 reservoir. Current HIV-1 cure strategies mainly focus on the concept of \"shock and kill\" to purge the viral reservoir. This approach aims to reactivate viral protein production in latently infected cells, which subsequently are eliminated as a consequence of viral replication, or recognized and killed by the immune system. Macrophage susceptibility to HIV-1 infection is dependent on the local microenvironment, suggesting that molecular pathways directing differentiation and polarization are involved. Current latency reversing agents (LRA) are mainly designed to reactivate the HIV-1 provirus in CD4+ T cells, while their ability to abolish viral latency in macrophages is largely unknown. Moreover, the resistance of macrophages to HIV-1 mediated kill and the presence of infected macrophages in immune privileged regions including the central nervous system (CNS), may pose a barrier to elimination of infected cells by current \"shock and kill\" strategies. This review focusses on the role of monocytes/macrophages in HIV-1 persistence. We will discuss mechanisms of viral latency and persistence in monocytes/macrophages. Furthermore, the role of these cells in HIV-1 tissue distribution and pathogenesis will be discussed.", "author": [{"author": "Zita Kruize", "affiliation": ["Laboratory for Viral Immune Pathogenesis, Department of Experimental Immunology, Amsterdam UMC, Amsterdam Infection & Immunity Institute, University of Amsterdam, Amsterdam, Netherlands."], "href": "/?term=Kruize+Z&cauthor_id=31866988"}, {"author": "Neeltje A Kootstra", "affiliation": ["Laboratory for Viral Immune Pathogenesis, Department of Experimental Immunology, Amsterdam UMC, Amsterdam Infection & Immunity Institute, University of Amsterdam, Amsterdam, Netherlands."], "href": "/?term=Kootstra+NA&cauthor_id=31866988"}], "refPMID": ["24556695", "29343578", "24827152", "24862328", "2295695", "16085226", "18575590", "19712453", "15481136", "14515355", "19239360", "19590405", "28714868", "22837004", "23846220", "25151491", "22972397", "8151287", "16647883", "22174685", "21966267", "2478293", "22020221", "16207172", "21364930", "26641855", "28680905", "22555163", "19372990", "15365096", "18513937", "23140174", "19034670", "30959264", "1631159", "22403404", "25540204", "20042468", "19414777", "30870200", "23852730", "15459189", "10371503", "18260759", "29670239", "28752134", "23094138", "26432022", "19961595", "7531918", "9449720", "12408230", "10888618", "25134819", "10985250", "26225566", "17056559", "21090961", "21925468", "11420724", "23092122", "23486877", "28239657", "17245432", "17475889", "8096068", "28967921", "23365428", "18261236", "11704885", "22176921", "1684706", "15254161", "10341273", "27576369", "30718846", "23187317", "15802963", "20966214", "19299747", "8464887", "24048477", "26303660", "12091904", "10823865", "16408017", "12907790", "14557656", "16873279", "9021050", "12208964", "21431677", "15163705", "27644592", "15843671", "23601688", "11940654", "22313961", "21135382", "31191911", "22674979", "9811724", "17306567", "2422213", "25902481", "28414330", "21720370", "17906637", "8099611", "11136236", "24472847", "16453265", "17538881", "17670825", "24804860", "26225771", "24277811", "30198905", "24121441", "21242887", "10393974", "18054979", "20924117", "29324227", "30194646", "7933078", "10644341", "7933130", "10400748", "21771346", "24453421", "18199649", "9419197", "21613998", "22327569", "15668551", "15519278", "22067449", "20380694", "16789841", "12368300", "22082156", "11100124", "17056765", "28978468", "23364796", "12843741", "15530839", "15849318", "17245431", "8289393", "19105661", "27492475", "21424110", "10451162", "19609362", "9826729", "25356757", "19509260", "18675436", "9226003", "7527834", "27986871", "12554797", "19029990", "24403590", "8870845", "21133815", "8287624", "3011909", "27058351", "17150965", "9882290", "19000723", "9188531", "20663914", "26355217", "2296295", "11154208", "2478233", "28606987", "11000244", "17371941", "24074301", "12634367", "12163571", "9539783", "16936559", "10733565", "9078201", "15579285", "23370291", "15049426", "1370293", "17721099", "12692243", "27466425", "30425153", "2121193", "19390619", "12202041", "1556179", "22442384", "12438635", "22406268", "19609198", "21637819", "19153236", "15627032", "8277180", "19996937", "12499197", "12775422", "8648722", "11192864", "15767660", "3639953", "22820791", "15034056", "19148268", "17907802", "10066379", "23518577", "27926762", "9060651", "8566032", "11604510", "28799997", "17322031", "30040863", "18007589", "22405323", "16337983", "9420250", "17190836", "8344262", "27062926", "9696868", "28321215", "19015395", "16989610", "19100594", "24296810", "3018755", "25340088", "23922698", "22227964", "11689886", "21653326", "28878233", "21771347", "23273845", "24322272", "20471997", "18761423", "9854115", "11914580", "10558989", "15681422", "20628149", "12944487"], "citedInPMID": ["31866988", "34835203", "34790202", "34631899", "34597340", "34356516", "34296319", "34233649", "34198973", "33980592", "33897659", "33868195", "33762317", "33672232", "33669846", "33669408", "33594125", "33524474", "33431684", "33400091", "33396807", "33328304", "33167728", "33114165", "33072075", "33037140", "32994328", "32849638", "32764670", "32754142", "32630058", "32252352", "32091411"], "body": " AbstractCurrent antiretroviral therapy (ART) effectively suppresses Human Immunodeficiency Virus type 1 (HIV-1) in infected individuals. However, even long term ART does not eradicate HIV-1 infected cells and the virus persists in cellular reservoirs. Beside memory CD4+ T cells, cells of the myeloid lineage, especially macrophages, are believed to be an important sanctuary for HIV-1. Monocytes and macrophages are key players in the innate immune response to pathogens and are recruited to sites of infection and inflammation. Due to their long life span and ability to reside in virtually every tissue, macrophages have been proposed to play a critical role in the establishment and persistence of the HIV-1 reservoir. Current HIV-1 cure strategies mainly focus on the concept of \u201cshock and kill\u201d to purge the viral reservoir. This approach aims to reactivate viral protein production in latently infected cells, which subsequently are eliminated as a consequence of viral replication, or recognized and killed by the immune system. Macrophage susceptibility to HIV-1 infection is dependent on the local microenvironment, suggesting that molecular pathways directing differentiation and polarization are involved. Current latency reversing agents (LRA) are mainly designed to reactivate the HIV-1 provirus in CD4+ T cells, while their ability to abolish viral latency in macrophages is largely unknown. Moreover, the resistance of macrophages to HIV-1 mediated kill and the presence of infected macrophages in immune privileged regions including the central nervous system (CNS), may pose a barrier to elimination of infected cells by current \u201cshock and kill\u201d strategies. This review focusses on the role of monocytes/macrophages in HIV-1 persistence. We will discuss mechanisms of viral latency and persistence in monocytes/macrophages. Furthermore, the role of these cells in HIV-1 tissue distribution and pathogenesis will be discussed.Keywords: HIV-1, monocytes/macrophages, latency, pathogenesis, reservoir IntroductionAntiretroviral therapy (ART) has dramatically improved the clinical outcome of Human Immunodeficiency Virus type 1 (HIV-1) infection. However, eradication of HIV-1 is not achieved due to persistence of a viral reservoir that harbors latent provirus that is reactivated upon discontinuation of ART. This latent viral reservoir is a major hurdle in curative treatment of HIV-1 infection and therefore new therapeutic approaches that aim to eliminate or reduce the viral reservoir are explored.CD4+ T cells and cells from the monocyte/macrophage lineage are considered as the most important target cells for HIV-1, and play an important role in viral persistence and the formation of the viral reservoir. While the major viral reservoir in treated HIV-1 infection is comprised of CD4+ T cells, the distribution and characteristics of the monocyte/macrophage reservoir remain largely unknown.Monocytes and macrophages are part of the innate immune system and respond to different signals which will direct macrophage differentiation, polarization and function. Monocytes/macrophages sense and clear pathogens, serve as antigen presenting cells priming the adaptive immune response, are involved in both pro- and anti-inflammatory responses, and tissue repair. Macrophages are found in all lymphoid as well as non-lymphoid tissues and their origin was originally described to be dependent on circulating monocytes, which would replenish the tissue-resident macrophage pool if needed. Recent studies in mice showed that the majority of tissue-resident macrophages are embryonically derived and have been implicated to be self-renewing, with the exception of the mucosal/border tissues like the intestine, the dermis and the heart, where bone marrow-derived circulating monocytes constantly replenish the aging tissue-resident macrophage pool (Ginhoux et al., 2010; Schulz et al., 2012; Hashimoto et al., 2013; Yona et al., 2013; Bain et al., 2014; Hoeffel et al., 2015; Mass et al., 2016). The proportion between the pool of tissue-resident macrophages and the pool of monocytes-derived macrophages vary during a state of homeostasis or inflammation (Wang and Kubes, 2016).Upon differentiation of monocytes into macrophages, these cells become susceptible to HIV-1 infection and due to their ability to migrate into tissues, they contribute to the spread of viral infection to nearly every tissue of the body including gut, semen, lung, gut-associated lymphoid tissue, brain, liver, urethra, and lymph nodes (Zhang et al., 1998; Mayer et al., 1999; Lambotte et al., 2005; Guadalupe et al., 2006; Poles et al., 2006; Chun et al., 2008; Zalar et al., 2010; Deleage et al., 2011; Abbas et al., 2014; Yukl et al., 2014; Cribbs et al., 2015; Hansen et al., 2016; Rose et al., 2016; Kandathil et al., 2018; Tso et al., 2018; Ganor et al., 2019; Ko et al., 2019). Furthermore, macrophages are considered long lived, resistant to virally induced cytopathic effects, and can reside in anatomical sanctuaries with restricted penetration of ART, which will support viral persistent even during ART (Ho et al., 1986; Nicholson et al., 1986; Lafeuillade et al., 1998; Solas et al., 2003; Estes et al., 2017; Clayton et al., 2018).In this review we will discuss the role of monocytes/macrophages in HIV-1 pathogenesis, HIV-1 persistence and viral reservoir. Monocytes and Macrophages in HIV-1 PathogenesisHIV-1 TransmissionHuman Immunodeficiency Virus type 1 enters the body mostly through mucosal surfaces of the genital or gastrointestinal tract. The underlying lamina propria is populated with high populations of lymphocytes and macrophages, which express CD4 in combination with the coreceptor C-C chemokine receptor type 5 (CCR5) and serve as targets for HIV-1 infection. Although the CD4+ T cells in the lamina propria are considered the major target for HIV-1 (Zhang et al., 1999; Greenhead et al., 2000; Gupta et al., 2002; Guadalupe et al., 2003; Brenchley et al., 2004; Hladik et al., 2007), infection of macrophages located in the lamina propria of the intestinal, penile urethral and vaginal mucosa has been described (Shen et al., 2009; Zalar et al., 2010; Ganor et al., 2013; Josefsson et al., 2013; Yukl et al., 2014). This confirms a role for macrophages during the early phases of infection, however, it remains under debate whether these mucosal macrophages support HIV-1 replication and spread the infection. Indeed, HIV-1 RNA has been demonstrated to be present in macrophages located in the vagina (Shen et al., 2009), but not in the gut, indicating that local environmental signals required for efficient viral replication in macrophages can be lacking in local mucosal tissues under homeostatic conditions.Monocytes in HIV-1 InfectionHuman Immunodeficiency Virus type 1 infection is characterized by high immune activation and inflammation, caused by high levels of HIV-1 replication, bacterial translocation, coinfection with other viruses (e.g., CMV, HCV, HBV) and, immune dysregulation (Brenchley and Douek, 2008; Deeks, 2011). ART strongly reduces HIV-1 associated inflammation and immune activation, however, residual immune activation and inflammation is still observed even in effectively treated individuals (Brenchley and Douek, 2008; Deeks, 2011). During HIV-1 infection, increased activation and differentiation of peripheral blood monocytes is also observed (Allen et al., 1990; Thieblemont et al., 1995; Pulliam et al., 1997; Ancuta et al., 2008; Hearps et al., 2012; Williams et al., 2012; Westhorpe et al., 2014; Booiman et al., 2017), which may affect their susceptibility to HIV-1 infection and their ability to migrate into the tissues, thus contributing to HIV-1 pathogenesis.In the peripheral blood, three monocyte subpopulations can be distinguished based on the expression of the LPS receptor CD14 and the Fc\u03b3III receptor CD16. The majority of the peripheral blood monocytes (>85%) are classical monocytes that express high levels of CD14 (CD14++CD16-), whereas CD16 is co-expressed on the intermediate (CD14++CD16+) and non-classical monocytes (CD14+CD16+) (Passlick et al., 1989; Ziegler-Heitbrock et al., 2010; Wong et al., 2011). Murine studies and more recently a humanized mouse study showed that monocyte precursors differentiate first into classical monocytes in bone marrow for a maturation phase of \u223c 38 h. This classical monocyte population is retained in the bone marrow and can respond to acute systemic inflammation. Most classical monocytes remain in the circulation for approximately 1\u20133 day before migration into the tissues. However, a small proportion matures further into intermediate monocytes within the circulation and most of these cells finally mature into non-classical monocytes before leaving the circulation (Sunderkotter et al., 2004; Varol et al., 2007; Yona et al., 2013; Gamrekelashvili et al., 2016; Patel et al., 2017). In HIV-1 infected individuals, an expansion of CD16 expressing monocytes or intermediate monocytes (CD14+CD16+) is evident during all phases of infection, especially in viremic individuals, which is normalized after initiation of ART in at least part of the patients (Allen et al., 1990; Thieblemont et al., 1995; Pulliam et al., 1997; Ancuta et al., 2008; Hearps et al., 2012; Williams et al., 2012; Westhorpe et al., 2014; Booiman et al., 2017). Moreover, monocytes express increased levels of activation markers (e.g., CD163, HLA-DR, CD69), T-cell costimulatory molecules (e.g., CD40 and CD86), adhesion molecules (e.g., CD11b, CD11c, CD91, CX3CR1), and chemokine receptors (e.g., C-C chemokine receptor type 2 (CCR2), CCR5), which is also observed during ART (Pulliam et al., 1997; Ancuta et al., 2008; Hearps et al., 2012; Westhorpe et al., 2014; Booiman et al., 2017).In the peripheral blood, a small population (<0.1%) of the monocytes harbor replication competent HIV-1 provirus (Furtado et al., 1999; Crowe and Sonza, 2000; Sonza et al., 2001; Shiramizu et al., 2005; Ellery et al., 2007). While classical monocytes are relatively resistant to HIV-1 infection most likely due to low CCR5 expression, CD16+ or intermediate monocytes express higher levels of CCR5 and can be infected by HIV-1 (Ellery et al., 2007; Ancuta et al., 2008). Indeed, CD16+ or intermediate monocytes have been demonstrated to harbor proviral DNA in untreated as well as treated HIV-1 infection (Shiramizu et al., 2005; Jaworowski et al., 2006, 2007; Ellery et al., 2007).Tissue Macrophages as HIV-1 ReservoirsMacrophages can be found in all lymphoid as well as non-lymphoid tissues and could therefore serve as a tissue reservoir for HIV-1 (Figure 1). In the lamina propria of mucosal tissues like the gastro intestinal tract, penile urethra and vagina, HIV-1 infection of local macrophages has been demonstrated in tissues from healthy individuals in vitro (Shen et al., 2009; Ganor et al., 2013), and in vivo in HIV-1 infected untreated (Josefsson et al., 2013) and ART treated individuals (Zalar et al., 2010; Josefsson et al., 2013; Yukl et al., 2014; Ganor et al., 2019). Although, HIV-1 DNA has been readily detected in these mucosal tissues, viral RNA has been demonstrated only in vaginal and urethral macrophages (Shen et al., 2009; Ganor et al., 2019). Moreover, replication competent HIV-1 could be isolated from urethral macrophages (Ganor et al., 2019). In contrast, HIV-1 proviral integration could not be detected in macrophages from colon of ART treated HIV-1 infected individuals (Cattin et al., 2019), and therefore it seems unlikely that these cells contribute to the replication competent HIV-1 reservoir (Shen et al., 2011).Open in a separate windowFIGURE 1Tissue distribution and anatomical sanctuaries of latently infected macrophages. Macrophages can be found in all lymphoid as well as non-lymphoid tissues and could therefore serve as a tissue reservoir for Human Immunodeficiency Virus type 1(HIV-1). This figure summarizes findings on HIV-1 latency in monocytes/macrophages in vivo, showing anatomical sanctuaries, the presence of HV-1 DNA and RNA and whether the virus was replication competent or not.In lymphoid tissues like spleen and lymph node, CD4+ T cells (resting memory cells) are the predominant reservoir, however, latently infected resident macrophages have been detected at low frequencies in lymph nodes (Embretson et al., 1993; Orenstein et al., 1997). HIV-1 residing in lymphoid tissues does not genetically differ from variants circulating in the blood, which suggest that there is no compartmentalization of HIV-1 in lymphoid tissue (Ball et al., 1994; van\u2019t Wout et al., 1998). However, genetic diversity of HIV-1 and independent viral evolution in monocytes and CD4+ T cells during the course of infection in treated and untreated patients suggests cellular compartmentalization (Fulcher et al., 2004; Llewellyn et al., 2006).Tissue resident macrophages like Kupffer cells in the liver have been demonstrated to be susceptible to HIV-1 infection, and persistence of HIV-1 in Kupffer cells has been demonstrated in HIV-1 infected individuals on ART (Schmitt et al., 1990; Hufert et al., 1993; Mosoian et al., 2017; Kandathil et al., 2018). However, virus particles produced by Kupffer cells could not be propagated in vitro using CEMx174 cells (Kandathil et al., 2018). Phylogenetic analysis of the viral quasi-species showed distinct clustering of viral variants in the liver, evident of compartmentalization of HIV-1 in the liver (Penton and Blackard, 2014). Also alveolar macrophages in the lung have been identified as HIV-1 targets, and HIV-1 persistence as determined by the presence of HIV-1 DNA and HIV-1 RNA has been demonstrated in patients, even during effective ART (Sierra-Madero et al., 1994; Jambo et al., 2014; Cribbs et al., 2015). Analysis of the HIV quasi-species also suggested compartmentalization of macrophage tropic HIV-1 variants in the lung (van\u2019t Wout et al., 1998).The central nervous system (CNS) has been identified as an important viral reservoir. HIV-1 enters the CNS through trafficking of infected cells across the blood brain barrier (BBB) which occurs already shortly after primary infection. Indeed, HIV-1 associated monocyte activation increases migratory abilities of peripheral monocytes by the upregulation of adhesion molecules and chemokine receptors, in response to for instance the monocyte chemoattractant protein 1 (MCP1) (Ancuta et al., 2004; Williams et al., 2013, 2014). In the CNS, HIV-1 persists predominantly in resident macrophages, like microglial cells and perivascular macrophages (Stoler et al., 1986; Wiley et al., 1986; Neuen-Jacob et al., 1993; Fischer-Smith et al., 2001; Cosenza et al., 2002; Ko et al., 2019). Genetic analysis of the viral quasi-species revealed compartmentalized viral replication in the CNS (Korber et al., 1994; van\u2019t Wout et al., 1998; Schnell et al., 2009).Although HIV-1 infection of macrophages has been demonstrated in different tissue, their role as a replication-competent reservoir remains under debate (Figure 1). Macrophages are terminally differentiated and their contribution to the viral reservoir is mainly dependent on their lifespan, whereas latently infected resting CD4+ memory T cells which are also long lived cells, contribute to the viral reservoir through homeostatic or antigen specific proliferation. However, recent reports have clearly demonstrated that macrophages can be infected in vivo and contribute to the viral reservoir (Figure 1; Micci et al., 2014; Clayton et al., 2017; DiNapoli et al., 2017). In SHIV infected rhesus macaques, in vivo viral replication was sustained by tissue macrophages upon CD4 T cell depletion (Igarashi et al., 2001). Moreover, HIV-1 persistence in macrophages was confirmed in HIV-1 infected humanized myeloid only mice in which viral rebound was observed in 33% of the animals following treatment interruption (Honeycutt et al., 2017).Macrophages in HIV-1 Related ComorbiditiesMonocytes and macrophages play a crucial role in several HIV-1 related comorbidities including neurological disorders, atherosclerosis and cardiovascular disease (CVD). HIV-1 associated neurocognitive disorders (HAND) describe a broad range of neurocognitive disorders from asymptomatic neurocognitive impairment, mild neurocognitive disorders (MND), and HIV-1 associated dementia (HAD). Although the use of ART has dramatically reduced development of HAD, milder forms of HAND are still highly prevalent amongst effectively treated HIV-1 infected individuals (Robertson et al., 2007; Heaton et al., 2010; Simioni et al., 2010). In HIV-1 infection, activated peripheral blood monocytes have increased migratory ability (Ancuta et al., 2004; Williams et al., 2013, 2014) and can cross the BBB, and therefore it is generally believed that HIV-1 infected peripheral monocytes are the main source of HIV-1 infection in the brain. Increased monocyte activation, expansion of the activated monocyte population as well as the level of HIV-1 DNA positive monocytes (CD14+/CD16+) have been associated with HIV-1 associated neuroinflammation and HAND (Pulliam et al., 1997, 2004; Shiramizu et al., 2005; Williams et al., 2014; Booiman et al., 2017). The ongoing neuroinflammation caused by monocyte activation and migration, is considered a strong mediator of neuronal damage in HAND. Moreover, persistent HIV-1 replication in resident macrophages and microglial cells of the brain, contributes to the ongoing neuroinflammation and neuronal damage. In particular the viral envelope protein gp120 (Giulian et al., 1993; Meucci et al., 1998; Kaul and Lipton, 1999; Ohagen et al., 1999), the HIV-1 accessory protein Vpr (Piller et al., 1998; Patel et al., 2000) and the HIV-1 transcriptional activator Tat (Liu et al., 2000; Park et al., 2001; Andras et al., 2003; Song et al., 2003) have been identified to contribute directly or indirectly to neurotoxicity.HIV-1 associated inflammation and immune activation, both risk factors in the onset of atherosclerosis and CVD, likely contribute to the increased risk of CVD in the HIV-1 infected population (Nou et al., 2016; Triant and Grinspoon, 2017). In early stages of atherosclerosis development, hyperlipidemia [(cholesterol, triglyceride, and low-density lipoprotein (LDL)] promotes the retention and uptake of LDL in the sub-endothelial space (Fogelstrand and Boren, 2012), which results in activation of endothelial cells and smooth muscle cells by the upregulation of adhesion molecules [intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion protein 1 (VCAM-1)] and secretion of chemokines [MCP-1 and macrophage colony-stimulating factor (M-CSF)] in the arterial wall (Frostegard et al., 1991). Cells of the immune system expressing the MCP-1 receptor CCR2, are recruited and can infiltrate the lesion (Frostegard et al., 1991). During HIV-1 infection, circulating activated monocytes express increased levels of CCR2, and have an increased ability to migrate in response to MCP1 into the arterial wall (Ancuta et al., 2004; Williams et al., 2013, 2014). These infiltrating monocytes further increase arterial inflammation by cytokine production [interleukin 1\u00df (IL-1\u00df) and IL-6] and uptake of (modified) lipoproteins, thereby accelerating atherosclerosis and CVD progression (Hansson, 2005). Indeed, it has been shown that aortic inflammation as measured by 18fluorodeoxyglucose uptake (18F-fluorodexoyglucose Positron Emission Tomography \u2013 Computed Tomography: 18F-FDG PET-CT) was increased in effectively treated HIV-1 infected patients to a degree resembling that of uninfected individuals with known CVD. Furthermore, 18F-FDG PET-CT activity was associated with serum levels of soluble CD163 (sCD163), a marker of monocyte/macrophage activation (Subramanian et al., 2012; Tawakol et al., 2017), clearly indicating a role of these cells in accelerated onset of atherosclerosis and CVD in HIV-1 infection. Mechanisms of HIV-1 LatencyMacrophage Differentiation and PolarizationHuman Immunodeficiency Virus type 1 infection in macrophages and their role in the viral reservoir are difficult to study in vivo and therefore in vitro culture models have been developed. In these models, monocytes are isolated from peripheral blood and differentiated in an in vitro culture system toward monocyte derived macrophages. In addition, different stimuli or cytokines can be added to the cultures in order to obtain phenotypically and functionally distinct macrophages. An advantage of this in vitro culture system is that large number of cells are available for analysis and macrophage activation, differentiation, polarization and function can easily be directed. A major disadvantage is that conditions in the culture system are not representative of the local environment in the different tissues, as tissue resident macrophages continuously respond to local signals influencing their function and phenotype resulting in a heterogeneous resident macrophage population. Recently, macrophages isolated from tissues of HIV-1 infected individuals have provided a better insight in the in vivo relevance and the state of the viral reservoir (latent, activated) (Zalar et al., 2010; Yukl et al., 2014; Cribbs et al., 2015; Kandathil et al., 2018; Ganor et al., 2019; Ko et al., 2019). However, these materials are difficult to obtain and invasive for the patient.In vitro, monocytes become highly susceptible to HIV-1 infection upon differentiation into macrophages (Rich et al., 1992; Schuitemaker et al., 1992; Sonza et al., 1996; Peng et al., 2007; Wang et al., 2009; Cobos Jimenez et al., 2012). Macrophages respond to different stimuli in their environment which will shape their physiology and function. Interferon-\u03b3 (IFN-\u03b3) and tumor necrosis factor-\u03b1 (TNF-\u03b1) polarize macrophages into an M1 or pro-inflammatory phenotype (Mosser, 2003). M2 or alternatively activated macrophages are generated upon exposure to IL-4 or IL-13 (M2a), immunoglobulin G (IgG) immune complexes and toll-like receptor (TLR) agonists (M2b) or IL-10 or glucocorticoids (M2c) (Mosser, 2003; Mantovani et al., 2004; Mosser and Edwards, 2008; Martinez et al., 2009). Polarization toward a M2a phenotype results in resistance to HIV-1 infection due to restrictions at the level of reverse transcription (Schuitemaker et al., 1992; Montaner et al., 1997; Wang et al., 1998; Cobos Jimenez et al., 2012), whereas polarization toward M1 or M2c inhibits viral replication at a transcriptional or post-transcriptional level (Kootstra et al., 1994; Montaner et al., 1994; Naif et al., 1996; Perez-Bercoff et al., 2003; David et al., 2006; Cassol et al., 2009, 2010; Cobos Jimenez et al., 2012). This data suggests that polarizing signals can induce viral latency in macrophages at both a pre- or post-integration level (Table 1).TABLE 1Cellular/viral factors involved in pre- and post-integration latency.Latency levelBlock in viral replication cycleCellular/viral factor involvedCell typeReferencesPre-integrationReverse transcriptionAPOBEC3AMonocytes/macrophages, monocytic cell linePeng et al., 2007; Miyagi et al., 2008; Berger G. et al., 2011Low dNTPs poolMacrophages, monocytic cell line;Kootstra et al., 2000; Lahouassa et al., 2012CD4+ T cellsKorin and Zack, 1999SAMHD1Macrophages, monocytic cell lines;Berger A. et al., 2011; Hrecka et al., 2011; Laguette et al., 2011; Lahouassa et al., 2012CD4+ T cellsBaldauf et al., 2012; Descours et al., 2012PAF1Monocytes/macrophages;Liu et al., 2011; Tyagi and Kashanchi, 2012CD4+ T cellsLiu et al., 2011; Tyagi and Kashanchi, 2012Nuclear importMX2Macrophages, monocytic cell lines;Goujon et al., 2013; Kane et al., 2013; Wang et al., 2017; Buffone et al., 2019CD4+ T cellsGoujon et al., 2013; Kane et al., 2013Post-integrationTranscriptional regulationSP1, CTIP2, SUV39H1, HDACs, c-myc, and HP1 in complexMonocytes/macrophages, monocytic cell linesRohr et al., 2003; Marban et al., 2005, 2007; du Chene et al., 2007; Desplats et al., 2013; Gray et al., 2016CD4+ T cells, T cell linesdu Chene et al., 2007; Jiang et al., 2007HDACs, CTIP2, YY1, CBF-1 and LSF in complexMonocytes/macrophages, monocytic cell lineBuescher et al., 2009T cell linesMargolis et al., 1994; Coull et al., 2000; He and Margolis, 2002; Tyagi and Karn, 2007CTIP2, LSD1, and hSET1/WDR5 in complexMonocytes/macrophages monocytic cell lineLe Douce et al., 2012DYRK1A and NFATMacrophagesBol et al., 2011CD4+ T cells, T cell lineBooiman et al., 2015; Heffern et al., 2019TCF-4, \u03b2-catenin, and SMAR1 complexMonocytes/macrophages, monocytic cell line, PBMCsKumar et al., 2008; Henderson et al., 2012; Aljawai et al., 2014CTIP2, Tat, and P-TEFbMonocytes/macrophages, monocytic T cellsHerrmann et al., 1998; Liou et al., 2002; Rice and Herrmann, 2003; Cherrier et al., 2013CD4+ T cellsHerrmann et al., 1998; Rice and Herrmann, 2003Transcription/TranslationmiRNAs (miR-17/92, miR-28, miR-150, miR-223 and miR-382)Monocytes/macrophages, monocytic cell lineSung and Rice, 2009; Wang et al., 2009; Lodge et al., 2017CD4+ T cells, T cell line, PBMCsHuang et al., 2007; Triboulet et al., 2007Nuclear exportMATR3, PSF and RevCD4+ T cellsSarracino et al., 2018TranslationG3BP1Monocytes/macrophagesCobos Jimenez et al., 2015CD4+ T cellCobos Jimenez et al., 2015Open in a separate windowMechanisms of Pre-integration LatencyIntegration of HIV-1 proviral DNA into the host genome is essential for viral replication. Upon entry into the cell, HIV-1 RNA is reverse transcribed, and subsequently the pre-integration complex (PIC), consisting of viral proteins (integrase, matrix, Vpr, capsid) and double stranded DNA (dsDNA) is assembled (Greene and Peterlin, 2002). The PIC is transported into the nucleus and where the proviral DNA integrates into the host cell genome. Pre-integration latency results when the viral replication cycle is partially or completely blocked at steps prior to integration (Table 1). Pre-integration latency is frequently observed in CD4+ T cells but was assumed not to be clinically relevant, because in vitro studies demonstrated that the unintegrated proviral DNA only persists for 1 day in these cells (Pierson et al., 2002; Zhou et al., 2005). However, in patients treated with ART, including an integrase inhibitor, unintegrated HIV-1 DNA subspecies where shown to persist in CD4+ T cells and can potentially integrate when integrase inhibitor medication is discontinued (Murray et al., 2014). Moreover, metabolically active macrophages can contain large quantities of unintegrated viral DNA, which remains stable and biologically active in non-dividing macrophages for up to 2 months (Gillim-Ross et al., 2005; Kelly et al., 2008). Therefore, unintegrated HIV-1 DNA in macrophages may contribute to the viral reservoir in HIV-1 pathogenesis. Indeed, some studies have reported detection of unintegrated HIV-1 DNA in macrophages from patients, mostly in the brain (Pang et al., 1990; Teo et al., 1997). In monocytes/macrophages pre-integration latency could be a consequence of poor reverse transcription efficiency due to a reduced deoxynucleotide triphosphates (dNTP) pool or inhibition of nuclear transport of the PIC as a consequence of low adenosine triphosphate (ATP) levels (Bukrinsky et al., 1992; Kootstra et al., 2000; Kennedy et al., 2010; Lahouassa et al., 2012). Several cellular factors have been implicated to play a role in the observed restriction in monocytes/macrophages: apolipoprotein B mRNA editing enzyme catalytic subunit 3G (APOBEC3G) and subunit 3A (APOBEC3A), a cellular deoxycytidine deaminases which induces G to A hypermutation and degradation of the HIV-1 genome (Peng et al., 2007; Miyagi et al., 2008; Berger G. et al., 2011); Sterile \u03b1-motif/histidine-aspartate domain-containing protein 1 (SAMHD1) which hydrolyses dNTPs into their precursors (nucleosides and triphosphates), in turn reducing the dNTPs pool and thereby limiting the reverse transcriptase activity (Berger A. et al., 2011; Hrecka et al., 2011; Laguette et al., 2011; Lahouassa et al., 2012); Myxovirus-resistance protein 2 (MX2) which inhibits HIV-1 replication post entry by hindering the nuclear accumulation and integration of proviral DNA into host chromatin (Goujon et al., 2013; Kane et al., 2013; Wang et al., 2017; Buffone et al., 2019); and members of the RNA polymerase II-associated factor 1 (PAF1) family, which are expressed in monocytes/macrophages and repress HIV-1 reverse transcription and proviral DNA integration (Liu et al., 2011; Tyagi and Kashanchi, 2012).Mechanisms of Post-integration LatencyPost-integration latency, which is established after integration of the HIV-1 proviral DNA into the host chromatin, is in contrast to pre-integration latency very stable and only limited by the lifespan of the infected cell. Mechanisms underlying HIV-1 latency in vivo are incompletely understood, however, it is a multifactorial phenomenon. Post-integration viral latency may be maintained at a transcriptional or a post-transcriptional level inhibiting HIV-1 protein production and virus formation. Several mechanisms acting at transcriptional and post-transcriptional level inducing HIV-1 latency in CD4+ T cells are well described. However, it is unknown whether these mechanism are also effective in cells of the monocyte/macrophage lineage. Nevertheless, several mechanisms inducing HIV-1 post-integration latency have been described in monocytes/macrophages, including chromatin environment, the absence of transcriptional activation, presence of transcriptional repressors and host antiviral processes. However, not all of these mechanisms are specific for post-integration latency in monocytes/macrophages (Table 1).Site of Integration and Chromatin Remodeling The host chromatin is organized into heterochromatin which is densely packed and transcriptionally silent and euchromatin which is loosely packed and transcriptionally active (Demeret et al., 2001). After nuclear import a transcriptional co-activator, lens epithelium-derived growth factor (LEDGF)/p75, which interacts with HIV-1 integrase (Vandegraaff et al., 2006; Meehan et al., 2009), targets the PIC mainly to intronic regions of actively transcribed genes (Schroder et al., 2002; Lewinski et al., 2006). The majority of silent HIV-1 provirus is integrated into the euchromatin, which seems paradoxical considering the fact that euchromatin is transcriptionally active (Han et al., 2004). Different mechanisms of transcriptional interference (e.g., steric hindrance, promotor occlusion and enhancer trapping) have been suggested as possible explanation for integrated proviral DNA expression suppression (Lassen et al., 2004; Bisgrove et al., 2005; Taube and Peterlin, 2013). Most of the data on HIV-1 integration and latency has been derived from CD4+ T cells. However, the integration of HIV-1 proviruses has also been studied in primary macrophages. Barr et al., for instance, studied HIV-1 DNA integration sites in primary macrophages by sequencing 754 unique integration sites and found that, similar to CD4+ T cells, HIV-1 also integrates preferentially into the transcriptionally active regions in macrophages (Mack et al., 2003; Barr et al., 2006; Wellensiek et al., 2009). In CD4+ T cells transcription gene silencing is the most favored mechanism for the establishment and maintenance of HIV-1 latency, whether this is also the case in monocytes/macrophages still has to be determined. However, it is well established that chromatin organization and reorganization influences the gene expression and that HIV-1 proviral DNA follows the same rules that apply to host genes. The role of histone H3 lysine 9 trimethylation (H3K9me3) in heterochromatin formation and the transcriptional silencing of integrated HIV-1 has been described (Grewal and Moazed, 2003; Stewart et al., 2005; du Chene et al., 2007; Marban et al., 2007). In addition, there are two nucleosomes, nuc-0 and nuc-1, that interact with the HIV-1 promoter irrespective of the HIV-1 integration site in the host genome. HIV-1 gene transcription from proviral DNA is only possible with the displacement of nuc-1 (Verdin et al., 1993). These studies were performed in the monocytic U1 cell line and collectively suggest that chromatin remodeling is an essential mechanism of HIV-1 latency establishment and regulation in monocytes/macrophages, however, these observations have not yet been confirmed in primary monocytes/macrophages.Transcriptional Regulation The integrated HIV-1 proviral DNA is flanked by the long terminal repeats (LTR). The 5\u2032LTR has binding sites for several transcription factors including specificity protein 1 (Sp1), activator protein 1 (AP1), nuclear factor of activated T-cells (NFAT), nuclear factor-\u03baB (NF-\u03baB), c-myc, chicken ovalbumin upstream promoter (COUP), upstream stimulatory factor (USF), CCAAT box transcription factor/nuclear factor 1 (CTF/NF1), T cell factor 1\u03b1 (TCF-1\u03b1) and the glucocorticoid receptor (Verdin et al., 1993). These transcription factors act together to regulate HIV-1 proviral DNA expression (Table 1). Sp1, for instance, recruits c-myc to the 5\u2032LTR of proviral DNA, which in turn recruits histone deacetylase 1 (HDAC1). HDAC1 then induces chromatin remodeling, which results in the suppression of HIV-1 gene expression (Jiang et al., 2007; Gray et al., 2016). In addition, HDACs were also shown to be recruited to the proviral promoter by COUP transcription factor interacting protein 2 (CTIP2), Ying Yang 1 (YY1), C-promoter binding factor-1 (CBF-1) and Late SV40 Factor (LSF), thereby promoting the establishment of latency (Coull et al., 2000; He and Margolis, 2002; Tyagi and Karn, 2007; Buescher et al., 2009; Le Douce et al., 2010). Similar results were observed in microglial cells, where CTIP2 has been shown to recruit both HDAC1 and HDAC2 to the 5\u2032LTR of HIV-1 proviral DNA (Marban et al., 2007). Moreover, CTIP2 also interacts with suppressor of variegation 3\u20139 homolog 1 (SUV39H1), a methyl transferase for H3K9me3 which subsequently promotes the recruitment of heterochromatin protein 1 (HP1) leading to local heterochromatization and induction of viral latency (Rohr et al., 2003; Marban et al., 2005; du Chene et al., 2007). The role of CTIP2 was further confirmed by Desplats et al. (2013) who analyzed the expression of CTIP2 in postmortem brain tissue of HIV-1 infected patients with HIV-1 encephalitis (HIV-1 DNA and RNA positive) and HIV-1 positive patients with latent HIV-1 (HIV-1 DNA positive and HIV-1 RNA negative) and no detectable HIV-1 (HIV-1 DNA negative) in the CNS. Higher amounts of CTIP2 were observed in the HIV-1 patients with latent HIV-1 in the CNS as compared to the other groups. Notably, CTIP2 was detected in microglial cells of patients with latent HIV-1, indicating that CTIP2 may play an important role in the regulation of viral latency in microglial cells (Desplats et al., 2013). Furthermore, lysine-specific demethylase 1 (LSD1) was found to regulate HIV-1 gene expression in a synergistic way with CTIP2 in microglial cells (Le Douce et al., 2012). LSD1 also assists in the recruitment of CTIP2 and human SET1/WD40-repeat protein 5 (hSET1/WDR5) at the Sp-1 binding sites of the HIV-1 proximal promoter, resulting in increased H3K4 trimethylation (H3K4me3), which in turn represses viral gene expression (Le Douce et al., 2012). This property of LSD1 seems to be highly specific for cells of the monocyte/macrophage lineage.Recently, the host factor dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) was shown to control HIV-1 replication by regulating HIV-1 provirus transcription in macrophages and CD4+ T cells (Bol et al., 2011; Booiman et al., 2015). DYRK1A was shown to regulate HIV-1 transcription via phosphorylation of the NFAT, thereby promoting NFAT translocation from the nucleus to the cytoplasm resulting in decreased viral transcription and latency. Chemical inhibition of DYRK1A resulted in an increased NFAT binding to the viral LTR and reactivating latent provirus (Bol et al., 2011; Booiman et al., 2015).Furthermore, it has been reported the 5\u2032LTR of the HIV-1 provirus contains multiple T cell factor 4 (TCF-4) binding sites. TCF-4 interacts with \u03b2-catenin and the scaffold matrix attachment region-binding protein 1 (SMAR1) at the 5\u2032LTR and this complex has been shown to repress HIV-1 proviral gene expression in different cell types including lymphocytes and astrocytes (Kumar et al., 2008; Henderson et al., 2012). \u03b2-catenin/TCF4 signaling has also been demonstrated to regulate HIV-1 replication in cells of the monocyte/macrophage lineage (Aljawai et al., 2014), which makes it plausible that these proteins also play a role in viral latency in these cells (Kumar et al., 2008).Apart from cellular factors, HIV-1 latency is also influenced by viral factors. HIV-1 replication requires the viral trans-activator protein Tat for efficient transcription and virus production. In the absence of Tat, only low level of HIV-1 transcription of mostly short abortive transcripts is observed (Karn, 2011). These short RNA transcripts contain a trans-activation response (TAR) element which is the binding site for the Tat protein (Berkhout et al., 1989). The positive transcription elongation factor (P-TEFb) is a critical cellular cofactor of Tat, that favors the generation of complete transcripts from HIV-1 proviral DNA (Price, 2000; Karn, 2011). P-TEFb is composed of a catalytic subunit, cyclin-dependent kinase 9 (CDK9), and a regulatory subunit, cyclin T1 (CycT1) (Herrmann et al., 1998; Rice and Herrmann, 2003; Bres et al., 2008). Tat binds to the TAR region of the RNA transcript and directs P-TEFb to the RNA polymerase II resulting in transcription of full-length HIV-1 RNA (Berkhout et al., 1989; Karn, 2011; Cherrier et al., 2013). The CDK2 can phosphorylate Ser90 on CDK9, thereby assisting in HIV-1 transcription (Ammosova et al., 2005; Breuer et al., 2012). Monocytes express very low levels of CycT1, which transiently increases during differentiation into macrophages. In contrast CDK9 expression levels remain constant in monocytes and macrophages (Liou et al., 2002). The low levels of CycT1 in monocytes result in low functional levels of P-TEFb, resulting in low HIV-1 transcription and thus viral latency in monocytes (Liou et al., 2002).Post-transcriptional Regulation Human Immunodeficiency Virus type 1 latency can also be regulated at a post-transcriptional level (Table 1). miRNAs are small single stranded non-coding RNAs that can regulate host gene expression at a post-transcriptional level. miRNAs have also been reported to influence HIV-1 gene expression (Huang et al., 2007; Sung and Rice, 2009; Haasnoot and Berkhout, 2011; Narayanan et al., 2011; Lodge et al., 2017). For instance, the miRNA cluster miR-17/92 is actively inhibited by HIV-1 to support efficient replication in different cell types including lymphocytes, monocytes and macrophages (Triboulet et al., 2007). Furthermore, miR-28; miR-150; miR-223; and miR-382 have been demonstrated to target HIV-1 and play a role in HIV-1 susceptibility of monocytes and macrophages. Inhibition of these miRNAs in monocytes results in increased HIV-1 replication, while increased expression of these miRNAs in macrophages decrease of HIV-1 replication (Huang et al., 2007; Wang et al., 2009). These data indicate that miRNAs can play an important role in viral latency in macrophages.RNA binding host proteins like GTPase-activating protein-(SH3 domain)-binding protein 1 (G3BP1) and the matrix-associated RNA binding protein Matrin 3 (MATR3), have been shown to play a role in the post-transcriptional regulation of HIV-1 latency. G3BP1 is a single-strand-specific endonuclease that binds mRNA transcripts at the 3\u2032UTR inside stress granules to control mRNA translation during cellular stress (Tourriere et al., 2001; Ortega et al., 2010). G3BP1 was shown to interact with HIV-1 mRNA transcripts thus preventing viral protein translation and restricting HIV-1 replication in T cells and macrophages (Cobos Jimenez et al., 2015). Resting T cells and IFN\u03b3 and TNF\u03b1 polarized macrophages, express high levels of G3BP1 indicating a role of this host factor in HIV-1 latency (Cobos Jimenez et al., 2015). MATR3 is a nuclear matrix protein that has the ability to bind DNA and RNA, and is involved in the regulation of gene expression and controls mRNA export from the nucleus. MATR3 also plays an essential role in Rev-mediated export of HIV-1 mRNA transcript from the nucleus (Kula et al., 2011; Yedavalli and Jeang, 2011), through the interaction with the polypyrimidine tract binding protein and associated splicing factor (PSF) and the viral protein Rev (Zolotukhin et al., 2003). Depletion of MATR3 was demonstrated to inhibit nuclear export of Rev responsive element (RRE)-containing viral RNAs resulting in decreased HIV-1 replication (Sarracino et al., 2018). Resting T cells only express low levels of MATR3 which increases upon activation, indicating a role of this protein in the establishment of latency in resting cells (Sarracino et al., 2018). Since MATR3 is also expressed in monocytes (Ancuta et al., 2009), it can be expected that it is also involved in the posttranscriptional regulation of HIV-1 in these cells. Eradication Strategies Targeting the Transcriptionally Latent ReservoirEven though ART has significantly increased life expectancy of HIV-1 infected individuals, complete eradication of the virus is not achievable without targeting the HIV-1 latent reservoirs. Currently, several therapeutic strategies are explored and early findings suggest that different strategies may be required to eliminate the different cellular viral reservoirs: memory CD4+ T cells which importantly maintain the viral reservoir through homeostatic- or antigen specific proliferation, and long lived cells like macrophages residing in the tissue.Latency ReversalThe latent viral reservoir is not recognized by the immune system and therefore these cells are not eliminated. The \u201cshock and kill\u201d strategy aims to induce viral protein production by reactivation of the latent HIV-1 provirus to prompt elimination of the infected cells through recognition by the immune system or cell death as a result of viral replication (Matalon et al., 2011; Badley et al., 2013). The \u201cshock and kill\u201d strategy has been investigated primarily using CD4+ T cells and T cell lines. Histone deacetylases (HDACs), for instance, are important for suppression of HIV-1 proviral DNA expression, and several HDAC inhibitors including SAHA, vorinostat, oxamflatin, metacept-1, and metacept-3 (Shehu-Xhilaga et al., 2009; Badley et al., 2013) have been studied for their ability to reactivate and eliminate latently infected cells. Although HDAC inhibitors have shown activity to reactivate HIV-1 from latent reservoirs in patients on ART, no decline in HIV-1 proviral DNA in CD4+ T cells was observed (Archin et al., 2009a, b, 2012, 2017). In contrast, in vitro studies in both the monocytic U1 cell line and monocyte-derived macrophages show that HDAC inhibitors not only reactivate and decrease HIV-1 release, but also degrades the viral particles through the canonical autophagy pathway (Shehu-Xhilaga et al., 2009; Rasmussen et al., 2013; Campbell et al., 2015). Moreover, several other compounds targeting different pathways have also been shown to effectively reactivate latent HIV-1, these include protein kinase C agonists (in vitro in both monocytic and T cell lines) (e.g., prostratin and ingenols) (Gulakowski et al., 1997; Korin and Zack, 1999; Warrilow et al., 2006; Colin and Van Lint, 2009; Abreu et al., 2014; Jiang et al., 2014, 2015; Darcis et al., 2015), histone methyltransferases inhibitors (in vitro in T cell lines and primary monocytes/macrophages and CD4+ T cells from HIV-1 infected ART treated patients) (Greiner et al., 2005; Miranda et al., 2009; Bernhard et al., 2011; Bouchat et al., 2012), anti-miRNA inhibitors (Zhang, 2009), NF-\u03baB activators (Fernandez et al., 2013; Kumar et al., 2013), and cytokine therapy in vitro and in vivo in CD4+ T cells as well as in cells of the monocyte/macrophage lineage (Chun et al., 1999; Scripture-Adams et al., 2002; Oguariri et al., 2007). Although the efficacy of the majority of these latency reversing agents (LRAs) has been demonstrated, a major hurdle in this treatment approach is that HIV-1 reactivation only occurs in a small subset of the latently infected cells, which might be overcome at least in part by the use of combinations of these LRAs. Furthermore, targeting of cellular factors and pathways identified to be involved in the regulation of HIV-1 latency at a transcription or post-transcription level, such as DYRK1A, \u03b2-catenin/TCF4 and Tat/pTEFb (Kumar et al., 2008; Aljawai et al., 2014; Booiman et al., 2015; Wu et al., 2017; Abner et al., 2018; Table 1) may improve the efficacy of latency reversal. Moreover, LRAs alone are mostly not sufficient to induce cell death and therefore an effective immune response is essential for the elimination of the reactivated cells and this is lacking in the majority of HIV-1 infected patients. Furthermore, HIV-1 infected macrophages can reside in immune privileged compartments like the CNS and can therefore not be reached by cytotoxic T cells (Shan et al., 2012; Badley et al., 2013).Apoptosis Inducing AgentsRecently more research is done into the \u201cPrime, Shock, and Kill\u201d method, where latent reservoirs are made sensitive to apoptosis (Prime), followed by reactivation of HIV-1 (Shock) and subsequently leading to cell death of the infected cell (Kill) (Badley et al., 2013). HIV-1 infection of CD4+ T cells and macrophages have been shown to induce an anti-apoptotic gene profile and resistance to apoptosis (Olivares et al., 2009). Several viral proteins have been associated with the resistance to apoptosis (Tanaka et al., 1999; Fernandez Larrosa et al., 2008): Vpr upregulates expression of anti-apoptotic proteins like B-cell lymphoma 2 (Bcl-2) in T cells only, thereby promoting cell survival (Conti et al., 1998). In monocytes/macrophages vpr facilitates HIV-1 replication (Connor et al., 1995). Tat, however, does upregulate Bcl-2 and X-linked inhibitor of apoptosis protein (XIAP) in both monocytes/macrophages and CD4+ T cells (Zhang et al., 2002; Lopez-Huertas et al., 2013); Nef upregulates the anti-apoptotic protein B-cell lymphoma-extra large (Bcl-Xl) in macrophages (Choi and Smithgall, 2004), while nef inactivates the Bcl-2-associated death promoter protein (BAD), a pro-apoptotic Bcl-2 family member, in a phosphoinositide 3-kinase (PI3K)\u2013 and p21-activated kinase (PAK)-dependent manner in T cells (Wolf et al., 2001); Furthermore, gp120 has been demonstrated to increase in expression of M-CSF in HIV-1 infected macrophages resulting in the upregulation of anti-apoptotic proteins [e.g., induced myeloid leukemia cell differentiation protein 1 (Mcl-1) and Bcl-2-related protein A1 (Bfl-1)] (Swingler et al., 2007). Therefore, targeting of the HIV-1 induced anti-apoptotic pathways during proviral reactivation strategies may promote cell death of the latently infected cells. Multiple agents targeting the anti-apoptotic pathways including PI3K/Protein kinase B (AKT) inhibitors, Bcl2 inhibitors and second mitochondria-derived activator of caspase (SMAC) mimetics/XIAP inhibitors, are explored for their ability to clear latently infected cells (Busca et al., 2012; Badley et al., 2013; Kim et al., 2018). SMAC mimetics/XIAP inhibitors, for instance, function by sensitizing macrophages to Vpr-induced cell death (Busca et al., 2012). In addition, SMAC mimetics/XIAP inhibitors can trigger transcription of latent proviruses via the non-canonical NF-\u03baB pathway. Furthermore, in vitro studies showed that combinations of HDAC inhibitors and SMAC/XIAP mimetics have synergistic activities in T cells (Pache et al., 2015). However, all these compounds do not specifically target the viral reservoir, and targeting of non-HIV-1 infected bystander cells will likely occur especially in ART-treated individuals with increased levels of immune activation, inflammation, and high prevalence of coinfections.Indeed, an apoptosis resistant gene expression signature was observed in monocytes from HIV-1 infected individuals (Giri et al., 2009). The circulating monocyte population is largely uninfected, which indicates that the anti-apoptotic expression profile may not be due to direct effects of viral infection. Moreover, in vitro infection of monocytes/macrophages demonstrated that HIV-1 infection, as well as exposure to HIV-1 or immune modulators increased apoptosis resistance (Giri et al., 2009). Concluding RemarksDespite effective treatment, HIV-1 infected patients are not cured because the virus is not eradicated and latently infected cells persist. The latent viral reservoir mainly resides in resting CD4+ T cells, however, latent HIV-1 proviruses have also been detected in cells of the monocyte/macrophage lineage. HIV-1 infected macrophages can be found in virtually every tissue including the CNS. Viral latency in cells of the monocyte/macrophage lineage can be regulated by diverse molecular mechanisms either at a transcriptional or post-transcriptional level and this is most likely dependent on the activation and differentiation state of these cells. Current eradication strategies rely on reactivation of the latent virus and subsequent kill of the infected cell. The majority of LRAs under study, have been shown to reactivate only small proportions of the latent HIV-1 reservoir, and therefore there is an urgent need for the development of new compounds that target different mechanisms of viral latency both in CD4+ T cells and monocytes/macrophages. Another hurdle is the lack of kill of latently infected cells upon reactivation, which is mainly due to an inefficient antiviral immune response and HIV-1 induced resistance to apoptosis. Apoptosis inducing compounds have been developed for cancer therapy, and their efficacy to specifically induce apoptosis in HIV-1 infected cells is currently under study.Cure research has mainly focused on CD4+ T cells, because these cells contribute to maintenance pf the viral reservoir through their long lifespan as well as their ability to proliferate under homeostatic conditions or in response to antigens. In contrast, macrophages are terminally differentiated and their contribution to the viral reservoir is mainly dependent on their lifespan and distribution to immune privileged tissues like the CNS. Although, these terminally differentiated latently infected macrophages cannot proliferate, they could be able to spread HIV-1 infection to CD4+ T cells upon reactivation of the virus by LRAs. Therefore, development of eradication strategies combining both novel LRAs and apoptosis inducing agents, targeting either specific cell types or ideally target both latently infected CD4+ T cells and monocytes/macrophages are needed. Author ContributionsZK and NK wrote and edited the review. Conflict of InterestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. ReferencesAbbas W., Khan K. A., Kumar A., Tripathy M. K., Dichamp I., Keita M., et al.  (2014). Blockade of BFA-mediated apoptosis in macrophages by the HIV-1 Nef protein.\nCell Death Dis.\n5:e1080. 10.1038/cddis.2014.16\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Abner E., Stoszko M., Zeng L., Chen H. C., Izquierdo-Bouldstridge A., Konuma T., et al.  (2018). A new quinoline BRD4 inhibitor targets a distinct latent HIV-1 reservoir for reactivation from other \u201cShock\u201d drugs.\nJ. Virol.\n92:e2056-17. 10.1128/JVI.02056-17\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Abreu C. M., Price S. L., Shirk E. N., Cunha R. D., Pianowski L. F., Clements J. E., et al.  (2014). Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.\nPLoS One\n9:e97257. 10.1371/journal.pone.0097257\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Aljawai Y., Richards M. H., Seaton M. S., Narasipura S. D., Al-Harthi L. (2014). beta-Catenin/TCF-4 signaling regulates susceptibility of macrophages and resistance of monocytes to HIV-1 productive infection.\nCurr. HIV Res.\n12\n164\u2013173. 10.2174/1570162x12666140526122249\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Allen J. B., McCartney-Francis N., Smith P. D., Simon G., Gartner S., Wahl L. M., et al.  (1990). Expression of interleukin 2 receptors by monocytes from patients with acquired immunodeficiency syndrome and induction of monocyte interleukin 2 receptors by human immunodeficiency virus in vitro.\nJ. Clin. Invest.\n85\n192\u2013199. 10.1172/JCI114412\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ammosova T., Berro R., Kashanchi F., Nekhai S. (2005). RNA interference directed to CDK2 inhibits HIV-1 transcription.\nVirology\n341\n171\u2013178. 10.1016/j.virol.2005.06.041\n [PubMed] [CrossRef] [Google Scholar]Ancuta P., Kamat A., Kunstman K. J., Kim E. Y., Autissier P., Wurcel A., et al.  (2008). Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients.\nPLoS One\n3:e2516. 10.1371/journal.pone.0002516\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ancuta P., Liu K. Y., Misra V., Wacleche V. S., Gosselin A., Zhou X., et al.  (2009). Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets.\nBMC Genomics\n10:403. 10.1186/1471-2164-10-403\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ancuta P., Moses A., Gabuzda D. (2004). Transendothelial migration of CD16+ monocytes in response to fractalkine under constitutive and inflammatory conditions.\nImmunobiology\n209\n11\u201320. 10.1016/j.imbio.2004.04.001\n [PubMed] [CrossRef] [Google Scholar]Andras I. E., Pu H., Deli M. A., Nath A., Hennig B., Toborek M. (2003). HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells.\nJ. Neurosci. Res.\n74\n255\u2013265. 10.1002/jnr.10762\n [PubMed] [CrossRef] [Google Scholar]Archin N. M., Espeseth A., Parker D., Cheema M., Hazuda D., Margolis D. M. (2009a). Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.\nAIDS Res. Hum. Retrovirus.\n25\n207\u2013212. 10.1089/aid.2008.0191\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Archin N. M., Keedy K. S., Espeseth A., Dang H., Hazuda D. J., Margolis D. M. (2009b). Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.\nAIDS\n23\n1799\u20131806. 10.1097/QAD.0b013e32832ec1dc\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Archin N. M., Kirchherr J. L., Sung J. A., Clutton G., Sholtis K., Xu Y., et al.  (2017). Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.\nJ. Clin. Invest.\n127\n3126\u20133135. 10.1172/JCI92684\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Archin N. M., Liberty A. L., Kashuba A. D., Choudhary S. K., Kuruc J. D., Crooks A. M., et al.  (2012). Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.\nNature\n487\n482\u2013485. 10.1038/nature11286\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Badley A. D., Sainski A., Wightman F., Lewin S. R. (2013). Altering cell death pathways as an approach to cure HIV infection.\nCell Death Dis.\n4:e718. 10.1038/cddis.2013.248\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Bain C. C., Bravo-Blas A., Scott C. L., Perdiguero E. G., Geissmann F., Henri S., et al.  (2014). Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice.\nNat. Immunol.\n15\n929\u2013937. 10.1038/ni.2967\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Baldauf H. M., Pan X., Erikson E., Schmidt S., Daddacha W., Burggraf M., et al.  (2012). SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells.\nNat. Med.\n18\n1682\u20131687. 10.1038/nm.2964\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ball J. K., Holmes E. C., Whitwell H., Desselberger U. (1994). Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy.\nJ. Gen. Virol.\n75(Pt 4), 67\u201379. 10.1099/0022-1317-75-4-867\n [PubMed] [CrossRef] [Google Scholar]Barr S. D., Ciuffi A., Leipzig J., Shinn P., Ecker J. R., Bushman F. D. (2006). HIV integration site selection: targeting in macrophages and the effects of different routes of viral entry.\nMol. Ther.\n14\n218\u2013225. 10.1016/j.ymthe.2006.03.012\n [PubMed] [CrossRef] [Google Scholar]Berger A., Sommer A. F., Zwarg J., Hamdorf M., Welzel K., Esly N., et al.  (2011). SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection.\nPLoS Pathog.\n7:e1002425. 10.1371/journal.ppat.1002425\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Berger G., Durand S., Fargier G., Nguyen X. N., Cordeil S., Bouaziz S., et al.  (2011). APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells.\nPLoS Pathog.\n7:e1002221. 10.1371/journal.ppat.1002221\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Berkhout B., Silverman R. H., Jeang K. T. (1989). Tat trans-activates the human immunodeficiency virus through a nascent RNA target.\nCell\n59\n273\u2013282. 10.1016/0092-8674(89)90289-4\n [PubMed] [CrossRef] [Google Scholar]Bernhard W., Barreto K., Saunders A., Dahabieh M. S., Johnson P., Sadowski I. (2011). The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response.\nFEBS Lett.\n585\n3549\u20133554. 10.1016/j.febslet.2011.10.018\n [PubMed] [CrossRef] [Google Scholar]Bisgrove D., Lewinski M., Bushman F., Verdin E. (2005). Molecular mechanisms of HIV-1 proviral latency.\nExpert Rev. Anti Infect. Ther.\n3\n805\u2013814. 10.1586/14787210.3.5.805\n [PubMed] [CrossRef] [Google Scholar]Bol S. M., Moerland P. D., Limou S., van Remmerden Y., Coulonges C., van Manen D., et al.  (2011). Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophages.\nPLoS One\n6:e17190. 10.1371/journal.pone.0017190\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Booiman T., Loukachov V. V., van Dort K. A., van\u2019t Wout A. B., Kootstra N. A. (2015). DYRK1A controls HIV-1 replication at a transcriptional level in an NFAT dependent manner.\nPLoS One\n10:e0144229. 10.1371/journal.pone.0144229\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Booiman T., Wit F. W., Maurer I., De Francesco D., Sabin C. A., Harskamp A. M., et al.  (2017). High cellular monocyte activation in people living with human immunodeficiency virus on combination antiretroviral therapy and lifestyle-matched controls is associated with greater inflammation in Cerebrospinal Fluid.\nOpen Forum Infect. Dis.\n4:ofx108. 10.1093/ofid/ofx108\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Bouchat S., Gatot J. S., Kabeya K., Cardona C., Colin L., Herbein G., et al.  (2012). Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.\nAIDS\n26\n1473\u20131482. 10.1097/QAD.0b013e32835535f5\n [PubMed] [CrossRef] [Google Scholar]Brenchley J. M., Douek D. C. (2008). The mucosal barrier and immune activation in HIV pathogenesis.\nCurr. Opin. HIV AIDS\n3\n356\u2013361. 10.1097/COH.0b013e3282f9ae9c\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Brenchley J. M., Schacker T. W., Ruff L. E., Price D. A., Taylor J. H., Beilman G. J., et al.  (2004). CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.\nJ. Exp. Med.\n200\n749\u2013759. 10.1084/jem.20040874\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Bres V., Yoh S. M., Jones K. A. (2008). The multi-tasking P-TEFb complex.\nCurr. Opin. Cell Biol.\n20\n334\u2013340. 10.1016/j.ceb.2008.04.008\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Breuer D., Kotelkin A., Ammosova T., Kumari N., Ivanov A., Ilatovskiy A. V., et al.  (2012). CDK2 regulates HIV-1 transcription by phosphorylation of CDK9 on serine 90.\nRetrovirology\n9:94. 10.1186/1742-4690-9-94\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Buescher J. L., Martinez L. B., Sato S., Okuyama S., Ikezu T. (2009). YY1 and FoxD3 regulate antiretroviral zinc finger protein OTK18 promoter activation induced by HIV-1 infection.\nJ. Neuroimmune Pharmacol.\n4\n103\u2013115. 10.1007/s11481-008-9139-x\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Buffone C., Kutzner J., Opp S., Martinez-Lopez A., Selyutina A., Coggings S. A., et al.  (2019). The ability of SAMHD1 to block HIV-1 but not SIV requires expression of MxB.\nVirology\n531\n260\u2013268. 10.1016/j.virol.2019.03.018\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Bukrinsky M. I., Sharova N., Dempsey M. P., Stanwick T. L., Bukrinskaya A. G., Haggerty S., et al.  (1992). Active nuclear import of human immunodeficiency virus type 1 preintegration complexes.\nProc. Natl. Acad. Sci. U.S.A.\n89\n6580\u20136584. 10.1073/pnas.89.14.6580\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Busca A., Saxena M., Kumar A. (2012). Critical role for antiapoptotic Bcl-xL and Mcl-1 in human macrophage survival and cellular IAP1/2 (cIAP1/2) in resistance to HIV-Vpr-induced apoptosis.\nJ. Biol. Chem.\n287\n15118\u201315133. 10.1074/jbc.M111.312660\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Campbell G. R., Bruckman R. S., Chu Y. L., Spector S. A. (2015). Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1.\nJ. Biol. Chem.\n290\n5028\u20135040. 10.1074/jbc.M114.605428\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Cassol E., Cassetta L., Alfano M., Poli G. (2010). Macrophage polarization and HIV-1 infection.\nJ. Leukoc. Biol.\n87\n599\u2013608. 10.1189/jlb.1009673\n [PubMed] [CrossRef] [Google Scholar]Cassol E., Cassetta L., Rizzi C., Alfano M., Poli G. (2009). M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms.\nJ. Immunol.\n182\n6237\u20136246. 10.4049/jimmunol.0803447\n [PubMed] [CrossRef] [Google Scholar]Cattin A., Wiche Salinas T. R., Gosselin A., Planas D., Shacklett B., Cohen E. A., et al.  (2019). HIV-1 is rarely detected in blood and colon myeloid cells during viral-suppressive antiretroviral therapy.\nAIDS\n33\n1293\u20131306. 10.1097/QAD.0000000000002195\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Cherrier T., Le Douce V., Eilebrecht S., Riclet R., Marban C., Dequiedt F., et al.  (2013). CTIP2 is a negative regulator of P-TEFb.\nProc. Natl. Acad. Sci. U.S.A.\n110\n12655\u201312660. 10.1073/pnas.1220136110\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Choi H. J., Smithgall T. E. (2004). HIV-1 Nef promotes survival of TF-1 macrophages by inducing Bcl-XL expression in an extracellular signal-regulated kinase-dependent manner.\nJ. Biol. Chem.\n279\n51688\u201351696. 10.1074/jbc.M410068200\n [PubMed] [CrossRef] [Google Scholar]Chun T. W., Engel D., Mizell S. B., Hallahan C. W., Fischette M., Park S., et al.  (1999). Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.\nNat. Med.\n5\n651\u2013655. 10.1038/9498\n [PubMed] [CrossRef] [Google Scholar]Chun T. W., Nickle D. C., Justement J. S., Meyers J. H., Roby G., Hallahan C. W., et al.  (2008). Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.\nJ. Infect. Dis.\n197\n714\u2013720. 10.1086/527324\n [PubMed] [CrossRef] [Google Scholar]Clayton K. L., Collins D. R., Lengieza J., Ghebremichael M., Dotiwala F., Lieberman J., et al.  (2018). Resistance of HIV-infected macrophages to CD8(+) T lymphocyte-mediated killing drives activation of the immune system.\nNat. Immunol.\n19\n475\u2013486. 10.1038/s41590-018-0085-3\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Clayton K. L., Garcia J. V., Clements J. E., Walker B. D. (2017). HIV infection of macrophages: implications for pathogenesis and cure.\nPathog. Immun.\n2\n179\u2013192. 10.20411/pai.v2i2.204\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Cobos Jimenez V., Booiman T., de Taeye S. W., van Dort K. A., Rits M. A., Hamann J., et al.  (2012). Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons.\nSci. Rep.\n2:763. 10.1038/srep00763\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Cobos Jimenez V., Martinez F. O., Booiman T., van Dort K. A., van de Klundert M. A., Gordon S., et al.  (2015). G3BP1 restricts HIV-1 replication in macrophages and T-cells by sequestering viral RNA.\nVirology\n486\n94\u2013104. 10.1016/j.virol.2015.09.007\n [PubMed] [CrossRef] [Google Scholar]Colin L., Van Lint C. (2009). Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.\nRetrovirology\n6:111. 10.1186/1742-4690-6-111\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Connor R. I., Chen B. K., Choe S., Landau N. R. (1995). Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.\nVirology\n206\n935\u2013944. 10.1006/viro.1995.1016\n [PubMed] [CrossRef] [Google Scholar]Conti L., Rainaldi G., Matarrese P., Varano B., Rivabene R., Columba S., et al.  (1998). The HIV-1 vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: possible implications for the pathogenesis of AIDS.\nJ. Exp. Med.\n187\n403\u2013413. 10.1084/jem.187.3.403\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Cosenza M. A., Zhao M. L., Si Q., Lee S. C. (2002). Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis.\nBrain Pathol.\n12\n442\u2013455. 10.1111/j.1750-3639.2002.tb00461.x\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Coull J. J., Romerio F., Sun J. M., Volker J. L., Galvin K. M., Davie J. R., et al.  (2000). The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.\nJ. Virol.\n74\n6790\u20136799. 10.1128/jvi.74.15.6790-6799.2000\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Cribbs S. K., Lennox J., Caliendo A. M., Brown L. A., Guidot D. M. (2015). Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages.\nAIDS Res. Hum. Retroviruses\n31\n64\u201370. 10.1089/AID.2014.0133\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Crowe S. M., Sonza S. (2000). HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication.\nJ. Leukoc. Biol.\n68\n345\u2013350.  [PubMed] [Google Scholar]Darcis G., Kula A., Bouchat S., Fujinaga K., Corazza F., Ait-Ammar A., et al.  (2015). An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified Bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression.\nPLoS Pathog.\n11:e1005063. 10.1371/journal.ppat.1005063\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]David A., Saez-Cirion A., Versmisse P., Malbec O., Iannascoli B., Herschke F., et al.  (2006). The engagement of activating FcgammaRs inhibits primate lentivirus replication in human macrophages.\nJ. Immunol.\n177\n6291\u20136300. 10.4049/jimmunol.177.9.6291\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Deeks S. G. (2011). HIV infection, inflammation, immunosenescence, and aging.\nAnnu. Rev. Med.\n62\n141\u2013155. 10.1146/annurev-med-042909-093756\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Deleage C., Moreau M., Rioux-Leclercq N., Ruffault A., Jegou B., Dejucq-Rainsford N. (2011). Human immunodeficiency virus infects human seminal vesicles in vitro and in vivo.\nAm. J. Pathol.\n179\n2397\u20132408. 10.1016/j.ajpath.2011.08.005\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Demeret C., Vassetzky Y., Mechali M. (2001). Chromatin remodelling and DNA replication: from nucleosomes to loop domains.\nOncogene\n20\n3086\u20133093. 10.1038/sj.onc.1204333\n [PubMed] [CrossRef] [Google Scholar]Descours B., Cribier A., Chable-Bessia C., Ayinde D., Rice G., Crow Y., et al.  (2012). SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells.\nRetrovirology\n9:87. 10.1186/1742-4690-9-87\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Desplats P., Dumaop W., Smith D., Adame A., Everall I., Letendre S., et al.  (2013). Molecular and pathologic insights from latent HIV-1 infection in the human brain.\nNeurology\n80\n1415\u20131423. 10.1212/WNL.0b013e31828c2e9e\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]DiNapoli S. R., Ortiz A. M., Wu F., Matsuda K., Twigg H. L., III, Hirsch V. M., et al.  (2017). Tissue-resident macrophages can contain replication-competent virus in antiretroviral-naive, SIV-infected Asian macaques.\nJCI Insight\n2:e91214. 10.1172/jci.insight.91214\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]du Chene I., Basyuk E., Lin Y. L., Triboulet R., Knezevich A., Chable-Bessia C., et al.  (2007). Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency.\nEMBO J.\n26\n424\u2013435. 10.1038/sj.emboj.7601517\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ellery P. J., Tippett E., Chiu Y. L., Paukovics G., Cameron P. U., Solomon A., et al.  (2007). The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo.\nJ. Immunol.\n178\n6581\u20136589. 10.4049/jimmunol.178.10.6581\n [PubMed] [CrossRef] [Google Scholar]Embretson J., Zupancic M., Ribas J. L., Burke A., Racz P., Tenner-Racz K., et al.  (1993). Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.\nNature\n362\n359\u2013362. 10.1038/362359a0\n [PubMed] [CrossRef] [Google Scholar]Estes J. D., Kityo C., Ssali F., Swainson L., Makamdop K. N., Del Prete G. Q., et al.  (2017). Defining total-body AIDS-virus burden with implications for curative strategies.\nNat. Med.\n23\n1271\u20131276. 10.1038/nm.4411\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Fernandez G., Zaikos T. D., Khan S. Z., Jacobi A. M., Behlke M. A., Zeichner S. L. (2013). Targeting IkappaB proteins for HIV latency activation: the role of individual IkappaB and NF-kappaB proteins.\nJ. Virol.\n87\n3966\u20133978. 10.1128/JVI.03251-12\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Fernandez Larrosa P. N., Croci D. O., Riva D. A., Bibini M., Luzzi R., Saracco M., et al.  (2008). Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway.\nRetrovirology\n5:19. 10.1186/1742-4690-5-19\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Fischer-Smith T., Croul S., Sverstiuk A. E., Capini C., L\u2019Heureux D., Regulier E. G., et al.  (2001). CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection.\nJ. Neurovirol.\n7\n528\u2013541. 10.1080/135502801753248114\n [PubMed] [CrossRef] [Google Scholar]Fogelstrand P., Boren J. (2012). Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis.\nNutr. Metab. Cardiovasc. Dis.\n22\n1\u20137. 10.1016/j.numecd.2011.09.007\n [PubMed] [CrossRef] [Google Scholar]Frostegard J., Haegerstrand A., Gidlund M., Nilsson J. (1991). Biologically modified LDL increases the adhesive properties of endothelial cells.\nAtherosclerosis\n90\n119\u2013126. 10.1016/0021-9150(91)90106-d\n [PubMed] [CrossRef] [Google Scholar]Fulcher J. A., Hwangbo Y., Zioni R., Nickle D., Lin X., Heath L., et al.  (2004). Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection.\nJ. Virol.\n78\n7883\u20137893. 10.1128/JVI.78.15.7883-7893.2004\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Furtado M. R., Callaway D. S., Phair J. P., Kunstman K. J., Stanton J. L., Macken C. A., et al.  (1999). Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.\nN. Engl. J. Med.\n340\n1614\u20131622. 10.1056/NEJM199905273402102\n [PubMed] [CrossRef] [Google Scholar]Gamrekelashvili J., Giagnorio R., Jussofie J., Soehnlein O., Duchene J., Briseno C. G., et al.  (2016). Regulation of monocyte cell fate by blood vessels mediated by Notch signalling.\nNat. Commun.\n7:12597. 10.1038/ncomms12597\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ganor Y., Real F., Sennepin A., Dutertre C. A., Prevedel L., Xu L., et al.  (2019). HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy.\nNat. Microbiol.\n4\n633\u2013644. 10.1038/s41564-018-0335-z\n [PubMed] [CrossRef] [Google Scholar]Ganor Y., Zhou Z., Bodo J., Tudor D., Leibowitch J., Mathez D., et al.  (2013). The adult penile urethra is a novel entry site for HIV-1 that preferentially targets resident urethral macrophages.\nMucosal. Immunol.\n6\n776\u2013786. 10.1038/mi.2012.116\n [PubMed] [CrossRef] [Google Scholar]Gillim-Ross L., Cara A., Klotman M. E. (2005). HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages.\nViral Immunol.\n18\n190\u2013196. 10.1089/vim.2005.18.190\n [PubMed] [CrossRef] [Google Scholar]Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., et al.  (2010). Fate mapping analysis reveals that adult microglia derive from primitive macrophages.\nScience\n330\n841\u2013845. 10.1126/science.1194637\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Giri M. S., Nebozyhn M., Raymond A., Gekonge B., Hancock A., Creer S., et al.  (2009). Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance.\nJ. Immunol.\n182\n4459\u20134470. 10.4049/jimmunol.0801450\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Giulian D., Wendt E., Vaca K., Noonan C. A. (1993). The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes.\nProc. Natl. Acad. Sci. U.S.A.\n90\n2769\u20132773. 10.1073/pnas.90.7.2769\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Goujon C., Moncorge O., Bauby H., Doyle T., Ward C. C., Schaller T., et al.  (2013). Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection.\nNature\n502\n559\u2013562. 10.1038/nature12542\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Gray L. R., Cowley D., Welsh C., Lu H. K., Brew B. J., Lewin S. R., et al.  (2016). CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies.\nMol. Psychiatry\n21\n574\u2013584. 10.1038/mp.2015.111\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Greene W. C., Peterlin B. M. (2002). Charting HIV\u2019s remarkable voyage through the cell: Basic science as a passport to future therapy.\nNat. Med.\n8\n673\u2013680. 10.1038/nm0702-673\n [PubMed] [CrossRef] [Google Scholar]Greenhead P., Hayes P., Watts P. S., Laing K. G., Griffin G. E., Shattock R. J. (2000). Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.\nJ. Virol.\n74\n5577\u20135586. 10.1128/jvi.74.12.5577-5586.2000\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Greiner D., Bonaldi T., Eskeland R., Roemer E., Imhof A. (2005). Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9.\nNat. Chem. Biol.\n1\n143\u2013145. 10.1038/nchembio721\n [PubMed] [CrossRef] [Google Scholar]Grewal S. I., Moazed D. (2003). Heterochromatin and epigenetic control of gene expression.\nScience\n301\n798\u2013802. 10.1126/science.1086887\n [PubMed] [CrossRef] [Google Scholar]Guadalupe M., Reay E., Sankaran S., Prindiville T., Flamm J., McNeil A., et al.  (2003). Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.\nJ. Virol.\n77\n11708\u201311717. 10.1128/jvi.77.21.11708-11717.2003\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Guadalupe M., Sankaran S., George M. D., Reay E., Verhoeven D., Shacklett B. L., et al.  (2006). Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection.\nJ. Virol.\n80\n8236\u20138247. 10.1128/JVI.00120-06\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Gulakowski R. J., McMahon J. B., Buckheit R. W., Jr., Gustafson K. R., Boyd M. R. (1997). Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV).\nAntiviral Res.\n33\n87\u201397. 10.1016/s0166-3542(96)01004-2\n [PubMed] [CrossRef] [Google Scholar]Gupta P., Collins K. B., Ratner D., Watkins S., Naus G. J., Landers D. V., et al.  (2002). Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system.\nJ. Virol.\n76\n9868\u20139876. 10.1128/jvi.76.19.9868-9876.2002\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Haasnoot J., Berkhout B. (2011). RNAi and cellular miRNAs in infections by mammalian viruses.\nMethods Mol. Biol.\n721\n23\u201341. 10.1007/978-1-61779-037-9_2\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Han Y., Lassen K., Monie D., Sedaghat A. R., Shimoji S., Liu X., et al.  (2004). Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes.\nJ. Virol.\n78\n6122\u20136133. 10.1128/JVI.78.12.6122-6133.2004\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Hansen E. C., Ransom M., Hesselberth J. R., Hosmane N. N., Capoferri A. A., Bruner K. M., et al.  (2016). Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells.\neLife\n5:e18447. 10.7554/eLife.18447\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Hansson G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease.\nN. Engl. J. Med.\n352\n1685\u20131695. 10.1056/NEJMra043430\n [PubMed] [CrossRef] [Google Scholar]Hashimoto D., Chow A., Noizat C., Teo P., Beasley M. B., Leboeuf M., et al.  (2013). Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes.\nImmunity\n38\n792\u2013804. 10.1016/j.immuni.2013.04.004\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]He G., Margolis D. M. (2002). Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat.\nMol. Cell Biol.\n22\n2965\u20132973. 10.1128/mcb.22.9.2965-2973.2002\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Hearps A. C., Maisa A., Cheng W. J., Angelovich T. A., Lichtfuss G. F., Palmer C. S., et al.  (2012). HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy.\nAIDS\n26\n843\u2013853. 10.1097/QAD.0b013e328351f756\n [PubMed] [CrossRef] [Google Scholar]Heaton R. K., Clifford D. B., Franklin DR, Jr., Woods S. P., Ake C., Vaida F., et al.  (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.\nNeurology\n75\n2087\u20132096. 10.1212/WNL.0b013e318200d727\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Heffern E. F., Ramani R., Marshall G., Kyei G. B. (2019). Identification of isoform-selective hydroxamic acid derivatives that potently reactivate HIV from latency.\nJ. Virus Erad.\n5\n84\u201391.  [PMC free article] [PubMed] [Google Scholar]Henderson L. J., Narasipura S. D., Adarichev V., Kashanchi F., Al-Harthi L. (2012). Identification of novel T cell factor 4 (TCF-4) binding sites on the HIV long terminal repeat which associate with TCF-4, beta-catenin, and SMAR1 to repress HIV transcription.\nJ. Virol.\n86\n9495\u20139503. 10.1128/JVI.00486-12\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Herrmann C. H., Carroll R. G., Wei P., Jones K. A., Rice A. P. (1998). Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines.\nJ. Virol.\n72\n9881\u20139888.  [PMC free article] [PubMed] [Google Scholar]Hladik F., Sakchalathorn P., Ballweber L., Lentz G., Fialkow M., Eschenbach D., et al.  (2007). Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.\nImmunity\n26\n257\u2013270. 10.1016/j.immuni.2007.01.007\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ho D. D., Rota T. R., Hirsch M. S. (1986). Infection of monocyte/macrophages by human T lymphotropic virus type III.\nJ. Clin. Invest.\n77\n1712\u20131715. 10.1172/JCI112491\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Hoeffel G., Chen J., Lavin Y., Low D., Almeida F. F., See P., et al.  (2015). C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages.\nImmunity\n42\n665\u2013678. 10.1016/j.immuni.2015.03.011\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Honeycutt J. B., Thayer W. O., Baker C. E., Ribeiro R. M., Lada S. M., Cao Y., et al.  (2017). HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy.\nNat. Med.\n23\n638\u2013643. 10.1038/nm.4319\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Hrecka K., Hao C., Gierszewska M., Swanson S. K., Kesik-Brodacka M., Srivastava S., et al.  (2011). Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.\nNature\n474\n658\u2013661. 10.1038/nature10195\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Huang J., Wang F., Argyris E., Chen K., Liang Z., Tian H., et al.  (2007). Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes.\nNat. Med.\n13\n1241\u20131247. 10.1038/nm1639\n [PubMed] [CrossRef] [Google Scholar]Hufert F. T., Schmitz J., Schreiber M., Schmitz H., Racz P., von Laer D. D. (1993). Human Kupffer cells infected with HIV-1 in vivo.\nJ. Acquir. Immune Defic. Syndr.\n6\n772\u2013777.  [PubMed] [Google Scholar]Igarashi T., Brown C. R., Endo Y., Buckler-White A., Plishka R., Bischofberger N., et al.  (2001). Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.\nProc. Natl. Acad. Sci. U.S.A.\n98\n658\u2013663. 10.1073/pnas.021551798\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Jambo K. C., Banda D. H., Kankwatira A. M., Sukumar N., Allain T. J., Heyderman R. S., et al.  (2014). Small alveolar macrophages are infected preferentially by HIV and exhibit impaired phagocytic function.\nMucosal. Immunol.\n7\n1116\u20131126. 10.1038/mi.2013.127\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Jaworowski A., Ellery P., Maslin C. L., Naim E., Heinlein A. C., Ryan C. E., et al.  (2006). Normal CD16 expression and phagocytosis of Mycobacterium avium complex by monocytes from a current cohort of HIV-1-infected patients.\nJ. Infect. Dis.\n193\n693\u2013697. 10.1086/500367\n [PubMed] [CrossRef] [Google Scholar]Jaworowski A., Kamwendo D. D., Ellery P., Sonza S., Mwapasa V., Tadesse E., et al.  (2007). CD16+ monocyte subset preferentially harbors HIV-1 and is expanded in pregnant Malawian women with Plasmodium falciparum malaria and HIV-1 infection.\nJ. Infect. Dis.\n196\n38\u201342. 10.1086/518443\n [PubMed] [CrossRef] [Google Scholar]Jiang G., Espeseth A., Hazuda D. J., Margolis D. M. (2007). c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter.\nJ. Virol.\n81\n10914\u201310923. 10.1128/JVI.01208-07\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Jiang G., Mendes E. A., Kaiser P., Sankaran-Walters S., Tang Y., Weber M. G., et al.  (2014). Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cdelta-NF-kappaB signaling.\nAIDS\n28\n1555\u20131566. 10.1097/QAD.0000000000000289\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Jiang G., Mendes E. A., Kaiser P., Wong D. P., Tang Y., Cai I., et al.  (2015). Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation.\nPLoS Pathog.\n11:e1005066. 10.1371/journal.ppat.1005066\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Josefsson L., von Stockenstrom S., Faria N. R., Sinclair E., Bacchetti P., Killian M., et al.  (2013). The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time.\nProc. Natl. Acad. Sci. U.S.A.\n110\nE4987\u2013E4996. 10.1073/pnas.1308313110\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kandathil A. J., Sugawara S., Goyal A., Durand C. M., Quinn J., Sachithanandham J., et al.  (2018). No recovery of replication-competent HIV-1 from human liver macrophages.\nJ. Clin. Invest.\n128\n4501\u20134509. 10.1172/JCI121678\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kane M., Yadav S. S., Bitzegeio J., Kutluay S. B., Zang T., Wilson S. J., et al.  (2013). MX2 is an interferon-induced inhibitor of HIV-1 infection.\nNature\n502\n563\u2013566. 10.1038/nature12653\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Karn J. (2011). The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit.\nCurr. Opin. HIV AIDS\n6\n4\u201311. 10.1097/COH.0b013e328340ffbb\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kaul M., Lipton S. A. (1999). Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis.\nProc. Natl. Acad. Sci. U.S.A.\n96\n8212\u20138216. 10.1073/pnas.96.14.8212\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kelly J., Beddall M. H., Yu D., Iyer S. R., Marsh J. W., Wu Y. (2008). Human macrophages support persistent transcription from unintegrated HIV-1 DNA.\nVirology\n372\n300\u2013312. 10.1016/j.virol.2007.11.007\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kennedy E. M., Gavegnano C., Nguyen L., Slater R., Lucas A., Fromentin E., et al.  (2010). Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages.\nJ. Biol. Chem.\n285\n39380\u201339391. 10.1074/jbc.M110.178582\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kim Y., Anderson J. L., Lewin S. R. (2018). Getting the \u201cKill\u201d into \u201cShock and Kill\u201d: Strategies to Eliminate Latent HIV.\nCell Host Microbe\n23\n14\u201326. 10.1016/j.chom.2017.12.004\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ko A., Kang G., Hattler J. B., Galadima H. I., Zhang J., Li Q., et al.  (2019). Macrophages but not astrocytes harbor HIV DNA in the brains of HIV-1-infected aviremic individuals on suppressive antiretroviral therapy.\nJ. Neuroimmune Pharmacol.\n14\n110\u2013119. 10.1007/s11481-018-9809-2\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kootstra N. A., van\u2019t Wout A., Huisman H. G., Miedema F., Schuitemaker H. (1994). Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages.\nJ. Virol.\n68\n6967\u20136975.  [PMC free article] [PubMed] [Google Scholar]Kootstra N. A., Zwart B. M., Schuitemaker H. (2000). Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle.\nJ. Virol.\n74\n1712\u20131717. 10.1128/jvi.74.4.1712-1717.2000\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Korber B. T., Kunstman K. J., Patterson B. K., Furtado M., McEvilly M. M., Levy R., et al.  (1994). Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences.\nJ. Virol.\n68\n7467\u20137481.  [PMC free article] [PubMed] [Google Scholar]Korin Y. D., Zack J. A. (1999). Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes.\nJ. Virol.\n73\n6526\u20136532.  [PMC free article] [PubMed] [Google Scholar]Kula A., Guerra J., Knezevich A., Kleva D., Myers M. P., Marcello A. (2011). Characterization of the HIV-1 RNA associated proteome identifies Matrin 3 as a nuclear cofactor of Rev function.\nRetrovirology\n8:60. 10.1186/1742-4690-8-60\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kumar A., Abbas W., Herbein G. (2013). TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?\nMediators Inflamm.\n2013:484378. 10.1155/2013/484378\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kumar A., Zloza A., Moon R. T., Watts J., Tenorio A. R., Al-Harthi L. (2008). Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells.\nJ. Virol.\n82\n2813\u20132820. 10.1128/JVI.02498-07\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lafeuillade A., Chollet L., Hittinger G., Profizi N., Costes O., Poggi C. (1998). Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL.\nJ. Infect. Dis.\n177\n235\u2013238. 10.1086/517362\n [PubMed] [CrossRef] [Google Scholar]Laguette N., Sobhian B., Casartelli N., Ringeard M., Chable-Bessia C., Segeral E., et al.  (2011). SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx.\nNature\n474\n654\u2013657. 10.1038/nature10117\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lahouassa H., Daddacha W., Hofmann H., Ayinde D., Logue E. C., Dragin L., et al.  (2012). SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates.\nNat. Immunol.\n13\n223\u2013228. 10.1038/ni.2236\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lambotte O., Chaix M. L., Gasnault J., Goujard C., Lebras P., Delfraissy J. F., et al.  (2005). Persistence of replication-competent HIV in the central nervous system despite long-term effective highly active antiretroviral therapy.\nAIDS\n19\n217\u2013218. 10.1097/00002030-200501280-00018\n [PubMed] [CrossRef] [Google Scholar]Lassen K., Han Y., Zhou Y., Siliciano J., Siliciano R. F. (2004). The multifactorial nature of HIV-1 latency.\nTrends Mol. Med.\n10\n525\u2013531. 10.1016/j.molmed.2004.09.006\n [PubMed] [CrossRef] [Google Scholar]Le Douce V., Colin L., Redel L., Cherrier T., Herbein G., Aunis D., et al.  (2012). LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing.\nNucleic Acids Res.\n40\n1904\u20131915. 10.1093/nar/gkr857\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Le Douce V., Herbein G., Rohr O., Schwartz C. (2010). Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage.\nRetrovirology\n7:32. 10.1186/1742-4690-7-32\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lewinski M. K., Yamashita M., Emerman M., Ciuffi A., Marshall H., Crawford G., et al.  (2006). Retroviral DNA integration: viral and cellular determinants of target-site selection.\nPLoS Pathog.\n2:e60. 10.1371/journal.ppat.0020060\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Liou L. Y., Herrmann C. H., Rice A. P. (2002). Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function.\nJ. Virol.\n76\n10579\u201310587. 10.1128/jvi.76.21.10579-10587.2002\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Liu L., Oliveira N. M., Cheney K. M., Pade C., Dreja H., Bergin A. M., et al.  (2011). A whole genome screen for HIV restriction factors.\nRetrovirology\n8:94. 10.1186/1742-4690-8-94\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Liu Y., Jones M., Hingtgen C. M., Bu G., Laribee N., Tanzi R. E., et al.  (2000). Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands.\nNat. Med.\n6\n1380\u20131387. 10.1038/82199\n [PubMed] [CrossRef] [Google Scholar]Llewellyn N., Zioni R., Zhu H., Andrus T., Xu Y., Corey L., et al.  (2006). Continued evolution of HIV-1 circulating in blood monocytes with antiretroviral therapy: genetic analysis of HIV-1 in monocytes and CD4+ T cells of patients with discontinued therapy.\nJ. Leukoc. Biol.\n80\n1118\u20131126. 10.1189/jlb.0306144\n [PubMed] [CrossRef] [Google Scholar]Lodge R., Ferreira Barbosa J. A., Lombard-Vadnais F., Gilmore J. C., Deshiere A., Gosselin A., et al.  (2017). Host MicroRNAs-221 and -222 inhibit HIV-1 entry in macrophages by targeting the CD4 viral receptor.\nCell Rep.\n21\n141\u2013153. 10.1016/j.celrep.2017.09.030\n [PubMed] [CrossRef] [Google Scholar]Lopez-Huertas M. R., Mateos E., Sanchez Del Cojo M., Gomez-Esquer F., Diaz-Gil G., Rodriguez-Mora S., et al.  (2013). The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+ T lymphocytes: a potential mechanism for persistent viral production.\nJ. Biol. Chem.\n288\n7626\u20137644. 10.1074/jbc.M112.408294\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Mack K. D., Jin X., Yu S., Wei R., Kapp L., Green C., et al.  (2003). HIV insertions within and proximal to host cell genes are a common finding in tissues containing high levels of HIV DNA and macrophage-associated p24 antigen expression.\nJ. Acquir. Immune Defic. Syndr.\n33\n308\u2013320. 10.1097/00126334-200307010-00004\n [PubMed] [CrossRef] [Google Scholar]Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. (2004). The chemokine system in diverse forms of macrophage activation and polarization.\nTrends Immunol.\n25\n677\u2013686. 10.1016/j.it.2004.09.015\n [PubMed] [CrossRef] [Google Scholar]Marban C., Redel L., Suzanne S., Van Lint C., Lecestre D., Chasserot-Golaz S., et al.  (2005). COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells.\nNucleic Acids Res.\n33\n2318\u20132331. 10.1093/nar/gki529\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Marban C., Suzanne S., Dequiedt F., de Walque S., Redel L., Van Lint C., et al.  (2007). Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing.\nEMBO J.\n26\n412\u2013423. 10.1038/sj.emboj.7601516\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Margolis D. M., Somasundaran M., Green M. R. (1994). Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production.\nJ. Virol.\n68\n905\u2013910.  [PMC free article] [PubMed] [Google Scholar]Martinez F. O., Helming L., Gordon S. (2009). Alternative activation of macrophages: an immunologic functional perspective.\nAnnu. Rev. Immunol.\n27\n451\u2013483. 10.1146/annurev.immunol.021908.132532\n [PubMed] [CrossRef] [Google Scholar]Mass E., Ballesteros I., Farlik M., Halbritter F., Gunther P., Crozet L., et al.  (2016). Specification of tissue-resident macrophages during organogenesis.\nScience\n353:aaf4238. 10.1126/science.aaf4238\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Matalon S., Rasmussen T. A., Dinarello C. A. (2011). Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.\nMol. Med.\n17\n466\u2013472. 10.2119/molmed.2011.00076\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Mayer K. H., Boswell S., Goldstein R., Lo W., Xu C., Tucker L., et al.  (1999). Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy.\nClin. Infect. Dis.\n28\n1252\u20131259. 10.1086/514775\n [PubMed] [CrossRef] [Google Scholar]Meehan A. M., Saenz D. T., Morrison J. H., Garcia-Rivera J. A., Peretz M., Llano M., et al.  (2009). LEDGF/p75 proteins with alternative chromatin tethers are functional HIV-1 cofactors.\nPLoS Pathog.\n5:e1000522. 10.1371/journal.ppat.1000522\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Meucci O., Fatatis A., Simen A. A., Bushell T. J., Gray P. W., Miller R. J. (1998). Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity.\nProc. Natl. Acad. Sci. U.S.A.\n95\n14500\u201314505. 10.1073/pnas.95.24.14500\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Micci L., Alvarez X., Iriele R. I., Ortiz A. M., Ryan E. S., McGary C. S., et al.  (2014). CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells.\nPLoS Pathog.\n10:e1004467. 10.1371/journal.ppat.1004467\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Miranda T. B., Cortez C. C., Yoo C. B., Liang G., Abe M., Kelly T. K., et al.  (2009). DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.\nMol. Cancer Ther.\n8\n1579\u20131588. 10.1158/1535-7163.MCT-09-0013\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Miyagi E., Schwartzkopff F., Plishka R., Buckler-White A., Clouse K. A., Strebel K. (2008). APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages.\nVirology\n379\n266\u2013274. 10.1016/j.virol.2008.06.033\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Montaner L. J., Bailer R. T., Gordon S. (1997). IL-13 acts on macrophages to block the completion of reverse transcription, inhibit virus production, and reduce virus infectivity.\nJ. Leukoc. Biol.\n62\n126\u2013132. 10.1002/jlb.62.1.126\n [PubMed] [CrossRef] [Google Scholar]Montaner L. J., Griffin P., Gordon S. (1994). Interleukin-10 inhibits initial reverse transcription of human immunodeficiency virus type 1 and mediates a virostatic latent state in primary blood-derived human macrophages in vitro.\nJ. Gen. Virol.\n75(Pt 12), 3393\u20133400. 10.1099/0022-1317-75-12-3393\n [PubMed] [CrossRef] [Google Scholar]Mosoian A., Zhang L., Hong F., Cunyat F., Rahman A., Bhalla R., et al.  (2017). Frontline science: HIV infection of Kupffer cells results in an amplified proinflammatory response to LPS.\nJ. Leukoc. Biol.\n101\n1083\u20131090. 10.1189/jlb.3HI0516-242R\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Mosser D. M. (2003). The many faces of macrophage activation.\nJ. Leukoc. Biol.\n73\n209\u2013212. 10.1189/jlb.0602325\n [PubMed] [CrossRef] [Google Scholar]Mosser D. M., Edwards J. P. (2008). Exploring the full spectrum of macrophage activation.\nNat. Rev. Immunol.\n8\n958\u2013969. 10.1038/nri2448\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Murray J. M., Zaunders J. J., McBride K. L., Xu Y., Bailey M., Suzuki K., et al.  (2014). HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.\nJ. Virol.\n88\n3516\u20133526. 10.1128/JVI.03331-13\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Naif H. M., Chang J., Ho-Shon M., Li S., Cunningham A. L. (1996). Inhibition of human immunodeficiency virus replication in differentiating monocytes by interleukin 10 occurs in parallel with inhibition of cellular RNA expression.\nAIDS Res. Hum. Retroviruses\n12\n1237\u20131245. 10.1089/aid.1996.12.1237\n [PubMed] [CrossRef] [Google Scholar]Narayanan A., Kehn-Hall K., Bailey C., Kashanchi F. (2011). Analysis of the roles of HIV-derived microRNAs.\nExpert Opin. Biol. Ther.\n11\n17\u201329. 10.1517/14712598.2011.540564\n [PubMed] [CrossRef] [Google Scholar]Neuen-Jacob E., Arendt G., Wendtland B., Jacob B., Schneeweis M., Wechsler W. (1993). Frequency and topographical distribution of CD68-positive macrophages and HIV-1 core proteins in HIV-associated brain lesions.\nClin. Neuropathol.\n12\n315\u2013324.  [PubMed] [Google Scholar]Nicholson J. K., Cross G. D., Callaway C. S., McDougal J. S. (1986). In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV).\nJ. Immunol.\n137\n323\u2013329. [PubMed] [Google Scholar]Nou E., Lo J., Grinspoon S. K. (2016). Inflammation, immune activation, and cardiovascular disease in HIV.\nAIDS\n30\n1495\u20131509. 10.1097/QAD.0000000000001109\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Oguariri R. M., Brann T. W., Imamichi T. (2007). Hydroxyurea and interleukin-6 synergistically reactivate HIV-1 replication in a latently infected promonocytic cell line via SP1/SP3 transcription factors.\nJ. Biol. Chem.\n282\n3594\u20133604. 10.1074/jbc.M608150200\n [PubMed] [CrossRef] [Google Scholar]Ohagen A., Ghosh S., He J., Huang K., Chen Y., Yuan M., et al.  (1999). Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope.\nJ. Virol.\n73\n897\u2013906.  [PMC free article] [PubMed] [Google Scholar]Olivares I., Ballester A., Lombardia L., Dominguez O., Lopez-Galindez C. (2009). Human immunodeficiency virus type 1 chronic infection is associated with different gene expression in MT-4, H9 and U937 cell lines.\nVirus Res.\n139\n22\u201331. 10.1016/j.virusres.2008.09.010\n [PubMed] [CrossRef] [Google Scholar]Orenstein J. M., Fox C., Wahl S. M. (1997). Macrophages as a source of HIV during opportunistic infections.\nScience\n276\n1857\u20131861. 10.1126/science.276.5320.1857\n [PubMed] [CrossRef] [Google Scholar]Ortega A. D., Willers I. M., Sala S., Cuezva J. M. (2010). Human G3BP1 interacts with beta-F1-ATPase mRNA and inhibits its translation.\nJ. Cell Sci.\n123(Pt 16), 2685\u20132696. 10.1242/jcs.065920\n [PubMed] [CrossRef] [Google Scholar]Pache L., Dutra M. S., Spivak A. M., Marlett J. M., Murry J. P., Hwang Y., et al.  (2015). BIRC2/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by smac mimetics to promote reversal of viral latency.\nCell Host Microbe\n18\n345\u2013353. 10.1016/j.chom.2015.08.009\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Pang S., Koyanagi Y., Miles S., Wiley C., Vinters H. V., Chen I. S. (1990). High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients.\nNature\n343\n85\u201389. 10.1038/343085a0\n [PubMed] [CrossRef] [Google Scholar]Park I. W., Wang J. F., Groopman J. E. (2001). HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes.\nBlood\n97\n352\u2013358. 10.1182/blood.v97.2.352\n [PubMed] [CrossRef] [Google Scholar]Passlick B., Flieger D., Ziegler-Heitbrock H. W. (1989). Identification and characterization of a novel monocyte subpopulation in human peripheral blood.\nBlood\n74\n2527\u20132534. 10.1182/blood.v74.7.2527.2527\n [PubMed] [CrossRef] [Google Scholar]Patel A. A., Zhang Y., Fullerton J. N., Boelen L., Rongvaux A., Maini A. A., et al.  (2017). The fate and lifespan of human monocyte subsets in steady state and systemic inflammation.\nJ. Exp. Med.\n214\n1913\u20131923. 10.1084/jem.20170355\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Patel C. A., Mukhtar M., Pomerantz R. J. (2000). Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells.\nJ. Virol.\n74\n9717\u20139726. 10.1128/jvi.74.20.9717-9726.2000\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Peng G., Greenwell-Wild T., Nares S., Jin W., Lei K. J., Rangel Z. G., et al.  (2007). Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression.\nBlood\n110\n393\u2013400. 10.1182/blood-2006-10-051763\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Penton P. K., Blackard J. T. (2014). Analysis of HIV quasispecies suggests compartmentalization in the liver.\nAIDS Res. Hum. Retroviruses\n30\n394\u2013402. 10.1089/AID.2013.0146\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Perez-Bercoff D., David A., Sudry H., Barre-Sinoussi F., Pancino G. (2003). Fcgamma receptor-mediated suppression of human immunodeficiency virus type 1 replication in primary human macrophages.\nJ. Virol.\n77\n4081\u20134094. 10.1128/jvi.77.7.4081-4094.2003\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Pierson T. C., Zhou Y., Kieffer T. L., Ruff C. T., Buck C., Siliciano R. F. (2002). Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.\nJ. Virol.\n76\n8518\u20138531. 10.1128/jvi.76.17.8518-8513.2002\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Piller S. C., Jans P., Gage P. W., Jans D. A. (1998). Extracellular HIV-1 virus protein R causes a large inward current and cell death in cultured hippocampal neurons: implications for AIDS pathology.\nProc. Natl. Acad. Sci. U.S.A.\n95\n4595\u20134600. 10.1073/pnas.95.8.4595\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Poles M. A., Boscardin W. J., Elliott J., Taing P., Fuerst M. M., McGowan I., et al.  (2006). Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals.\nJ. Acquir. Immune Defic. Syndr.\n43\n65\u201368. 10.1097/01.qai.0000230524.71717.14\n [PubMed] [CrossRef] [Google Scholar]Price D. H. (2000). P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.\nMol. Cell Biol.\n20\n2629\u20132634. 10.1128/mcb.20.8.2629-2634.2000\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Pulliam L., Gascon R., Stubblebine M., McGuire D., McGrath M. S. (1997). Unique monocyte subset in patients with AIDS dementia.\nLancet\n349\n692\u2013695. 10.1016/S0140-6736(96)10178-1\n [PubMed] [CrossRef] [Google Scholar]Pulliam L., Sun B., Rempel H. (2004). Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load.\nJ. Neuroimmunol.\n157\n93\u201398. 10.1016/j.jneuroim.2004.08.039\n [PubMed] [CrossRef] [Google Scholar]Rasmussen T. A., Schmeltz Sogaard O., Brinkmann C., Wightman F., Lewin S. R., Melchjorsen J., et al.  (2013). Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.\nHum. Vaccin. Immunother.\n9\n993\u20131001. 10.4161/hv.23800\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Rice A. P., Herrmann C. H. (2003). Regulation of TAK/P-TEFb in CD4+ T lymphocytes and macrophages.\nCurr. HIV Res.\n1\n395\u2013404. 10.2174/1570162033485159\n [PubMed] [CrossRef] [Google Scholar]Rich E. A., Chen I. S., Zack J. A., Leonard M. L., O\u2019Brien W. A. (1992). Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1).\nJ. Clin. Invest.\n89\n176\u2013183. 10.1172/JCI115559\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Robertson K. R., Smurzynski M., Parsons T. D., Wu K., Bosch R. J., Wu J., et al.  (2007). The prevalence and incidence of neurocognitive impairment in the HAART era.\nAIDS\n21\n1915\u20131921. 10.1097/QAD.0b013e32828e4e27\n [PubMed] [CrossRef] [Google Scholar]Rohr O., Lecestre D., Chasserot-Golaz S., Marban C., Avram D., Aunis D., et al.  (2003). Recruitment of Tat to heterochromatin protein HP1 via interaction with CTIP2 inhibits human immunodeficiency virus type 1 replication in microglial cells.\nJ. Virol.\n77\n5415\u20135427. 10.1128/jvi.77.9.5415-5427.2003\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Rose R., Lamers S. L., Nolan D. J., Maidji E., Faria N. R., Pybus O. G., et al.  (2016). HIV maintains an evolving and dispersed population in multiple tissues during suppressive combined antiretroviral therapy in individuals with cancer.\nJ. Virol.\n90\n8984\u20138993. 10.1128/JVI.00684-16\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sarracino A., Gharu L., Kula A., Pasternak A. O., Avettand-Fenoel V., Rouzioux C., et al.  (2018). Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.\nmBio\n9:e2158-18. 10.1128/mBio.02158-18\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Schmitt M. P., Gendrault J. L., Schweitzer C., Steffan A. M., Beyer C., Royer C., et al.  (1990). Permissivity of primary cultures of human Kupffer cells for HIV-1.\nAIDS Res. Hum. Retroviruses\n6\n987\u2013991. 10.1089/aid.1990.6.987\n [PubMed] [CrossRef] [Google Scholar]Schnell G., Spudich S., Harrington P., Price R. W., Swanstrom R. (2009). Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia.\nPLoS Pathog.\n5:e1000395. 10.1371/journal.ppat.1000395\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Schroder A. R., Shinn P., Chen H., Berry C., Ecker J. R., Bushman F. (2002). HIV-1 integration in the human genome favors active genes and local hotspots.\nCell\n110\n521\u2013529. 10.1016/s0092-8674(02)00864-4\n [PubMed] [CrossRef] [Google Scholar]Schuitemaker H., Kootstra N. A., Koppelman M. H., Bruisten S. M., Huisman H. G., Tersmette M., et al.  (1992). Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages.\nJ. Clin. Invest.\n89\n1154\u20131160. 10.1172/JCI115697\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Schulz C., Gomez Perdiguero E., Chorro L., Szabo-Rogers H., Cagnard N., Kierdorf K., et al.  (2012). A lineage of myeloid cells independent of Myb and hematopoietic stem cells.\nScience\n336\n86\u201390. 10.1126/science.1219179\n [PubMed] [CrossRef] [Google Scholar]Scripture-Adams D. D., Brooks D. G., Korin Y. D., Zack J. A. (2002). Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype.\nJ. Virol.\n76\n13077\u201313082. 10.1128/jvi.76.24.13077-13082.2002\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Shan L., Deng K., Shroff N. S., Durand C. M., Rabi S. A., Yang H. C., et al.  (2012). Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.\nImmunity\n36\n491\u2013501. 10.1016/j.immuni.2012.01.014\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Shehu-Xhilaga M., Rhodes D., Wightman F., Liu H. B., Solomon A., Saleh S., et al.  (2009). The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells.\nAIDS\n23\n2047\u20132050. 10.1097/QAD.0b013e328330342c\n [PubMed] [CrossRef] [Google Scholar]Shen R., Meng G., Ochsenbauer C., Clapham P. R., Grams J., Novak L., et al.  (2011). Stromal down-regulation of macrophage CD4/CCR5 expression and NF-kappaB activation mediates HIV-1 non-permissiveness in intestinal macrophages.\nPLoS Pathog.\n7:e1002060. 10.1371/journal.ppat.1002060\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Shen R., Richter H. E., Clements R. H., Novak L., Huff K., Bimczok D., et al.  (2009). Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection.\nJ. Virol.\n83\n3258\u20133267. 10.1128/JVI.01796-08\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Shiramizu B., Gartner S., Williams A., Shikuma C., Ratto-Kim S., Watters M., et al.  (2005). Circulating proviral HIV DNA and HIV-associated dementia.\nAIDS\n19\n45\u201352. 10.1097/00002030-200501030-00005\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sierra-Madero J. G., Toossi Z., Hom D. L., Finegan C. K., Hoenig E., Rich E. A. (1994). Relationship between load of virus in alveolar macrophages from human immunodeficiency virus type 1-infected persons, production of cytokines, and clinical status.\nJ. Infect. Dis.\n169\n18\u201327. 10.1093/infdis/169.1.18\n [PubMed] [CrossRef] [Google Scholar]Simioni S., Cavassini M., Annoni J. M., Rimbault Abraham A., Bourquin I., Schiffer V., et al.  (2010). Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.\nAIDS\n24\n1243\u20131250. 10.1097/QAD.0b013e3283354a7b\n [PubMed] [CrossRef] [Google Scholar]Solas C., Lafeuillade A., Halfon P., Chadapaud S., Hittinger G., Lacarelle B. (2003). Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.\nAntimicrob. Agents Chemother.\n47\n238\u2013243. 10.1128/aac.47.1.238-243.2003\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Song L., Nath A., Geiger J. D., Moore A., Hochman S. (2003). Human immunodeficiency virus type 1 Tat protein directly activates neuronal N-methyl-D-aspartate receptors at an allosteric zinc-sensitive site.\nJ. Neurovirol.\n9\n399\u2013403. 10.1080/13550280390201704\n [PubMed] [CrossRef] [Google Scholar]Sonza S., Maerz A., Deacon N., Meanger J., Mills J., Crowe S. (1996). Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes.\nJ. Virol.\n70\n3863\u20133869.  [PMC free article] [PubMed] [Google Scholar]Sonza S., Mutimer H. P., Oelrichs R., Jardine D., Harvey K., Dunne A., et al.  (2001). Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy.\nAIDS\n15\n17\u201322. 10.1097/00002030-200101050-00005\n [PubMed] [CrossRef] [Google Scholar]Stewart M. D., Li J., Wong J. (2005). Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment.\nMol. Cell Biol.\n25\n2525\u20132538. 10.1128/MCB.25.7.2525-2538.2005\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Stoler M. H., Eskin T. A., Benn S., Angerer R. C., Angerer L. M. (1986). Human T-cell lymphotropic virus type III infection of the central nervous system. A preliminary in situ analysis.\nJAMA\n256\n2360\u20132364. 10.1001/jama.256.17.2360\n [PubMed] [CrossRef] [Google Scholar]Subramanian S., Tawakol A., Burdo T. H., Abbara S., Wei J., Vijayakumar J., et al.  (2012). Arterial inflammation in patients with HIV.\nJAMA\n308\n379\u2013386. 10.1001/jama.2012.6698\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sunderkotter C., Nikolic T., Dillon M. J., Van Rooijen N., Stehling M., Drevets D. A., et al.  (2004). Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response.\nJ. Immunol.\n172\n4410\u20134417. 10.4049/jimmunol.172.7.4410\n [PubMed] [CrossRef] [Google Scholar]Sung T. L., Rice A. P. (2009). miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1.\nPLoS Pathog.\n5:e1000263. 10.1371/journal.ppat.1000263\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Swingler S., Mann A. M., Zhou J., Swingler C., Stevenson M. (2007). Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein.\nPLoS Pathog.\n3:e0030134. 10.1371/journal.ppat.0030134\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Tanaka Y., Kameoka M., Ota K., Itaya A., Ikuta K., Yoshihara K. (1999). Establishment of persistent infection with HIV-1 abrogates the caspase-3-dependent apoptotic signaling pathway in U937 cells.\nExp. Cell Res.\n247\n514\u2013524. 10.1006/excr.1998.4376\n [PubMed] [CrossRef] [Google Scholar]Taube R., Peterlin M. (2013). Lost in transcription: molecular mechanisms that control HIV latency.\nViruses\n5\n902\u2013927. 10.3390/v5030902\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Tawakol A., Ishai A., Li D., Takx R. A., Hur S., Kaiser Y., et al.  (2017). Association of arterial and lymph node inflammation with distinct inflammatory pathways in human immunodeficiency virus infection.\nJAMA Cardiol.\n2\n163\u2013171. 10.1001/jamacardio.2016.4728\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Teo I., Veryard C., Barnes H., An S. F., Jones M., Lantos P. L., et al.  (1997). Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS.\nJ. Virol.\n71\n2928\u20132933.  [PMC free article] [PubMed] [Google Scholar]Thieblemont N., Weiss L., Sadeghi H. M., Estcourt C., Haeffner-Cavaillon N. (1995). CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection.\nEur. J. Immunol.\n25\n3418\u20133424. 10.1002/eji.1830251232\n [PubMed] [CrossRef] [Google Scholar]Tourriere H., Gallouzi I. E., Chebli K., Capony J. P., Mouaikel J., van der Geer P., et al.  (2001). RasGAP-associated endoribonuclease G3Bp: selective RNA degradation and phosphorylation-dependent localization.\nMol. Cell Biol.\n21\n7747\u20137760. 10.1128/MCB.21.22.7747-7760.2001\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Triant V. A., Grinspoon S. K. (2017). Epidemiology of ischemic heart disease in HIV.\nCurr. Opin. HIV AIDS\n12\n540\u2013547. 10.1097/COH.0000000000000410\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Triboulet R., Mari B., Lin Y. L., Chable-Bessia C., Bennasser Y., Lebrigand K., et al.  (2007). Suppression of microRNA-silencing pathway by HIV-1 during virus replication.\nScience\n315\n1579\u20131582. 10.1126/science.1136319\n [PubMed] [CrossRef] [Google Scholar]Tso F. Y., Kang G., Kwon E. H., Julius P., Li Q., West J. T., et al.  (2018). Brain is a potential sanctuary for subtype C HIV-1 irrespective of ART treatment outcome.\nPLoS One\n13:e0201325. 10.1371/journal.pone.0201325\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Tyagi M., Karn J. (2007). CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency.\nEMBO J.\n26\n4985\u20134995. 10.1038/sj.emboj.7601928\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Tyagi M., Kashanchi F. (2012). New and novel intrinsic host repressive factors against HIV-1: PAF1 complex, HERC5 and others.\nRetrovirology\n9:19. 10.1186/1742-4690-9-19\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Vandegraaff N., Devroe E., Turlure F., Silver P. A., Engelman A. (2006). Biochemical and genetic analyses of integrase-interacting proteins lens epithelium-derived growth factor (LEDGF)/p75 and hepatoma-derived growth factor related protein 2 (HRP2) in preintegration complex function and HIV-1 replication.\nVirology\n346\n415\u2013426. 10.1016/j.virol.2005.11.022\n [PubMed] [CrossRef] [Google Scholar]van\u2019t Wout A. B., Ran L. J., Kuiken C. L., Kootstra N. A., Pals S. T., Schuitemaker H. (1998). Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy.\nJ. Virol.\n72\n488\u2013496.  [PMC free article] [PubMed] [Google Scholar]Varol C., Landsman L., Fogg D. K., Greenshtein L., Gildor B., Margalit R., et al.  (2007). Monocytes give rise to mucosal, but not splenic, conventional dendritic cells.\nJ. Exp. Med.\n204\n171\u2013180. 10.1084/jem.20061011\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Verdin E., Paras P., Jr., Van Lint C. (1993). Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.\nEMBO J.\n12\n3249\u20133259. 10.1002/j.1460-2075.1993.tb05994.x\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Wang J., Kubes P. (2016). A reservoir of mature cavity macrophages that can rapidly invade visceral organs to affect tissue repair.\nCell\n165\n668\u2013678. 10.1016/j.cell.2016.03.009\n [PubMed] [CrossRef] [Google Scholar]Wang J., Roderiquez G., Oravecz T., Norcross M. A. (1998). Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression.\nJ. Virol.\n72\n7642\u20137647.  [PMC free article] [PubMed] [Google Scholar]Wang X., Wang H., Liu M. Q., Li J. L., Zhou R. H., Zhou Y., et al.  (2017). IFN-lambda inhibits drug-resistant HIV infection of macrophages.\nFront. Immunol.\n8:210. 10.3389/fimmu.2017.00210\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Wang X., Ye L., Hou W., Zhou Y., Wang Y. J., Metzger D. S., et al.  (2009). Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection.\nBlood\n113\n671\u2013674. 10.1182/blood-2008-09-175000\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Warrilow D., Gardner J., Darnell G. A., Suhrbier A., Harrich D. (2006). HIV type 1 inhibition by protein kinase C modulatory compounds.\nAIDS Res. Hum. Retroviruses\n22\n854\u2013864. 10.1089/aid.2006.22.854\n [PubMed] [CrossRef] [Google Scholar]Wellensiek B. P., Ramakrishnan R., Sundaravaradan V., Mehta R., Harris D. T., Ahmad N. (2009). Differential HIV-1 integration targets more actively transcribed host genes in neonatal than adult blood mononuclear cells.\nVirology\n385\n28\u201338. 10.1016/j.virol.2008.10.052\n [PubMed] [CrossRef] [Google Scholar]Westhorpe C. L., Maisa A., Spelman T., Hoy J. F., Dewar E. M., Karapanagiotidis S., et al.  (2014). Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals.\nImmunol. Cell Biol.\n92\n133\u2013138. 10.1038/icb.2013.84\n [PubMed] [CrossRef] [Google Scholar]Wiley C. A., Schrier R. D., Nelson J. A., Lampert P. W., Oldstone M. B. (1986). Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients.\nProc. Natl. Acad. Sci. U.S.A.\n83\n7089\u20137093. 10.1073/pnas.83.18.7089\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Williams D. W., Byrd D., Rubin L. H., Anastos K., Morgello S., Berman J. W. (2014). CCR2 on CD14(+)CD16(+) monocytes is a biomarker of HIV-associated neurocognitive disorders.\nNeurol. Neuroimmunol. Neuroinflamm.\n1:e36. 10.1212/NXI.0000000000000036\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Williams D. W., Calderon T. M., Lopez L., Carvallo-Torres L., Gaskill P. J., Eugenin E. A., et al.  (2013). Mechanisms of HIV entry into the CNS: increased sensitivity of HIV infected CD14+CD16+ monocytes to CCL2 and key roles of CCR2, JAM-A, and ALCAM in diapedesis.\nPLoS One\n8:e69270. 10.1371/journal.pone.0069270\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Williams D. W., Eugenin E. A., Calderon T. M., Berman J. W. (2012). Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis.\nJ. Leukoc. Biol.\n91\n401\u2013415. 10.1189/jlb.0811394\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Wolf D., Witte V., Laffert B., Blume K., Stromer E., Trapp S., et al.  (2001). HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apoptotic signals.\nNat. Med.\n7\n1217\u20131224. 10.1038/nm1101-1217\n [PubMed] [CrossRef] [Google Scholar]Wong K. L., Tai J. J., Wong W. C., Han H., Sem X., Yeap W. H., et al.  (2011). Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets.\nBlood\n118\ne16\u2013e31. 10.1182/blood-2010-12-326355\n [PubMed] [CrossRef] [Google Scholar]Wu J., Ao M. T., Shao R., Wang H. R., Yu D., Fang M. J., et al.  (2017). A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter.\nSci. Rep.\n7:10657. 10.1038/s41598-017-10728-w\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Yedavalli V. S., Jeang K. T. (2011). Matrin 3 is a co-factor for HIV-1 Rev in regulating post-transcriptional viral gene expression.\nRetrovirology\n8:61. 10.1186/1742-4690-8-61\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Yona S., Kim K. W., Wolf Y., Mildner A., Varol D., Breker M., et al.  (2013). Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis.\nImmunity\n38\n79\u201391. 10.1016/j.immuni.2012.12.001\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Yukl S. A., Sinclair E., Somsouk M., Hunt P. W., Epling L., Killian M., et al.  (2014). A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells.\nAIDS\n28\n439\u2013442. 10.1097/QAD.0000000000000166\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Zalar A., Figueroa M. I., Ruibal-Ares B., Bare P., Cahn P., de Bracco M. M., et al.  (2010). Macrophage HIV-1 infection in duodenal tissue of patients on long term HAART.\nAntiviral Res.\n87\n269\u2013271. 10.1016/j.antiviral.2010.05.005\n [PubMed] [CrossRef] [Google Scholar]Zhang H. (2009). Reversal of HIV-1 latency with anti-microRNA inhibitors.\nInt. J. Biochem. Cell Biol.\n41\n451\u2013454. 10.1016/j.biocel.2008.07.016\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Zhang H., Dornadula G., Beumont M., Livornese L., Jr., Van Uitert B., Henning K., et al.  (1998). Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.\nN. Engl. J. Med.\n339\n1803\u20131809. 10.1056/NEJM199812173392502\n [PubMed] [CrossRef] [Google Scholar]Zhang M., Li X., Pang X., Ding L., Wood O., Clouse K. A., et al.  (2002). Bcl-2 upregulation by HIV-1 Tat during infection of primary human macrophages in culture.\nJ. Biomed. Sci.\n9\n133\u2013139. 10.1007/bf02256024\n [PubMed] [CrossRef] [Google Scholar]Zhang Z., Schuler T., Zupancic M., Wietgrefe S., Staskus K. A., Reimann K. A., et al.  (1999). Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.\nScience\n286\n1353\u20131357. 10.1126/science.286.5443.1353\n [PubMed] [CrossRef] [Google Scholar]Zhou Y., Zhang H., Siliciano J. D., Siliciano R. F. (2005). Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells.\nJ. Virol.\n79\n2199\u20132210. 10.1128/JVI.79.4.2199-2210.2005\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ziegler-Heitbrock L., Ancuta P., Crowe S., Dalod M., Grau V., Hart D. N., et al.  (2010). Nomenclature of monocytes and dendritic cells in blood.\nBlood\n116\ne74\u2013e80. 10.1182/blood-2010-02-258558\n [PubMed] [CrossRef] [Google Scholar]Zolotukhin A. S., Michalowski D., Bear J., Smulevitch S. V., Traish A. M., Peng R., et al.  (2003). PSF acts through the human immunodeficiency virus type 1 mRNA instability elements to regulate virus expression.\nMol. Cell Biol.\n23\n6618\u20136630. 10.1128/mcb.23.18.6618-6630.2003\n [PMC free article] [PubMed] [CrossRef] [Google Scholar]"}